US20090105164A1

US20090105164A1 - Substituted indole-o-glucosides

Info

Publication number: US20090105164A1
Application number: US12/337,903
Authority: US
Inventors: Mary Pat Beavers; Mona Patel; Philip Rybczynski; Maud Urbanski; Xiaoyan Zhang
Original assignee: Individual
Current assignee: Individual
Priority date: 2003-08-01
Filing date: 2008-12-18
Publication date: 2009-04-23
Also published as: US20100009900A1; WO2005012243A2; US7511022B2; EP1680131A2; AU2004261664A1; US7820630B2; WO2005012243A3; EA200601554A1; EP1680131A4; TW200526678A; SG130189A1; AR048282A1; CA2549025A1; MY142777A; US20060293251A1; US7129220B2; US20050037981A1; EA010422B1

Abstract

Substituted indole-O-glucosides, compositions containing them, and methods of using them, for example for the treatment of diabetes and Syndrome X are disclosed.

Description

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims benefit of provisional application Ser. No. 60/579,758, filed 15 Jun. 2004; Ser. No. 60/519,155, filed 12 Nov. 2003; Ser. No. 60/491,523, filed 1 Aug. 2003; and Ser. No. 60/491,534, filed 1 Aug. 2003, each of which is incorporated by reference herein.

FIELD OF THE INVENTION

This invention relates to substituted indole-O-glucosides, compositions containing them, and methods of using them, for example, for the treatment or prophylaxis of diabetes and Syndrome X.

BACKGROUND OF THE INVENTION

Diabetes is a chronic disorder affecting carbohydrate, fat and protein metabolism in animals.
Type I diabetes mellitus, which comprises approximately 10% of all diabetes cases, was previously referred to as insulin-dependent diabetes mellitus (“IDDM”) or juvenile-onset diabetes. This disease is characterized by a progressive loss of insulin secretory function by beta cells of the pancreas. This characteristic is also shared by non-idiopathic, or “secondary”, diabetes having its origins in pancreatic disease. Type I diabetes mellitus is associated with the following clinical signs or symptoms: persistently elevated plasma glucose concentration or hyperglycemia; polyuria; polydipsia and/or hyperphagia; chronic microvascular complications such as retinopathy, nephropathy and neuropathy; and macrovascular complications such as hyperlipidemia and hypertension which can lead to blindness, end-stage renal disease, limb amputation and myocardial infarction.
Type II diabetes mellitus (non-insulin-dependent diabetes mellitus or NIDDM) is a metabolic disorder involving the dysregulation of glucose metabolism and impaired insulin sensitivity. Type II diabetes mellitus usually develops in adulthood and is associated with the body's inability to utilize or make sufficient insulin. In addition to the insulin resistance observed in the target tissues, patients suffering from type II diabetes mellitus have a relative insulin deficiency—that is, patients have lower than predicted insulin levels for a given plasma glucose concentration. Type II diabetes mellitus is characterized by the following clinical signs or symptoms: persistently elevated plasma glucose concentration or hyperglycemia; polyuria; polydipsia and/or hyperphagia; chronic microvascular complications such as retinopathy, nephropathy and neuropathy; and macrovascular complications such as hyperlipidemia and hypertension which can lead to blindness, end-stage renal disease, limb amputation and myocardial infarction.
Syndrome X, also termed Insulin Resistance Syndrome (IRS), Metabolic Syndrome, or Metabolic Syndrome X, is recognized in some 2% of diagnostic coronary catheterizations. Often disabling, it presents symptoms or risk factors for the development of Type II diabetes mellitus and cardiovascular disease, including impaired glucose tolerance (IGT), impaired fasting glucose (IFG), hyperinsulinemia, insulin resistance, dyslipidemia (e.g., high triglycerides, low HDL), hypertension and obesity.
Therapy for IDDM patients has consistently focused on administration of exogenous insulin, which may be derived from various sources (e.g., human, bovine, porcine insulin). The use of heterologous species material gives rise to formation of anti-insulin antibodies which have activity-limiting effects and result in progressive requirements for larger doses in order to achieve desired hypoglycemic effects.
Typical treatment of Type II diabetes mellitus focuses on maintaining the blood glucose level as near to normal as possible with lifestyle modification relating to diet and exercise, and when necessary, the treatment with anti-diabetic agents, insulin or a combination thereof. NIDDM that cannot be controlled by dietary management is treated with oral antidiabetic agents.
Although insulin resistance is not always treated in all Syndrome X patients, those who exhibit a prediabetic state (e.g., IGT, IFG), where fasting glucose levels may be higher than normal but not at the diabetes diagnostic criterion, is treated in some countries (e.g., Germany) with metformin to prevent diabetes. The anti-diabetic agents may be combined with pharmacological agents for the treatment of the concomitant co-morbidities (e.g., antihypertensives for hypertension, hypolipidemic agents for lipidemia).
First-line therapies typically include metformin and sulfonylureas as well as thiazolidinediones. Metformin monotherapy is a first line choice, particularly for treating type II diabetic patients who are also obese and/or dyslipidemic. Lack of an appropriate response to metformin is often followed by treatment with metformin in combination with sulfonylureas, thiazolidinediones, or insulin. Sulfonylurea monotherapy (including all generations of drugs) is also a common first line treatment option. Another first line therapy choice may be thiazolidinediones. Alpha glucosidase inhibitors are also used as first and second line therapies. Patients who do not respond appropriately to oral anti-diabetic monotherapy, are given combinations of the above-mentioned agents. When glycemic control cannot be maintained with oral antidiabetics alone, insulin therapy is used either as a monotherapy, or in combination with oral antidiabetic agents.
One recent development in treating hyperglycemia is focused on excretion of excessive glucose directly into urine. Specific inhibitors of SGLTs have been shown to increase the excretion of glucose in urine and lower blood glucose levels in rodent models of IDDM and NIDDM.

SUMMARY OF THE INVENTION

One aspect of the invention is directed to methods and compositions for the treatment or prophylaxis of diabetes, Syndrome X, or associated symptoms or complications. More specifically, this invention is directed to a novel method of treating diabetes or Syndrome X, or associated symptoms or complications thereof, in a subject afflicted with such a condition, said method comprising administering one or more glucose reabsorption inhibitors and administering one or more antidiabetic agent(s) for the treatment of diabetes or Syndrome X, or associated symptoms or complications thereof.
Another aspect of the invention features compounds of Formula (I):
wherein
R₁is H, C_1-4alkyl, or R₄R₅N—(CO)—; each of R₄and R₅is independently C_1-5alkyl;
R₂is H, F, Cl or C_1-4alkyl;
R₃is H or C_1-4alkyl, provided that when R₃is C_1-4alkyl, then R₂is H;
Q is —C═O—, or —(CH₂)_n— where n=0, 1, or 2;
P═H, C_1-7acyl, or (C_1-6alkoxy)carbonyl;
Z is substituted or unsubstituted, and is selected from C_3-7cycloalkyl, phenyl, 5- or 6-membered heterocyclyl having 1 or 2 heteroatoms independently selected from N, O, and S, a biaryl, and a 9- or 10-membered fused bicyclyl or fused heterobicyclyl, wherein said fused heterobicyclyl has between 1 and 4 heteroatoms (and preferably between 1 and 2 heteroatoms) independently selected from N, O, and S; or a pharmaceutically acceptable salt, thereof.
One aspect of the invention features a pharmaceutical composition comprising a glucose reabsorption inhibitor (alone or in combination with one or more additional antidiabetic agents), and a pharmaceutically acceptable carrier. The invention also provides a process for formulating a pharmaceutical composition, comprising formulating together a glucose reabsorption inhibitor, (optionally with at least one antidiabetic agent), and a pharmaceutically acceptable carrier.
An embodiment of the invention is a method for treating diabetes or Syndrome X, or associated symptoms or complications thereof in a subject, said method comprising administering to said subject a jointly effective amount of a glucose reabsorption inhibitor and administering to said subject a jointly effective amount of an antidiabetic agent, said combined administration providing the desired therapeutic effect.
Another embodiment of the invention is a method for inhibiting the onset of diabetes or Syndrome X, or associated symptoms or complications thereof in a subject, said method comprising administering to said subject a jointly effective dose of a glucose reabsorption inhibitor and administering to said subject a jointly effective amount of an one or more antidiabetic agent(s), said combined administration providing the desired prophylactic effect.
In the disclosed methods, the diabetes or Syndrome X, or associated symptoms or complications thereof, is selected from IDDM, NIDDM, IGT, IFG, obesity, nephropathy, neuropathy, retinopathy, atherosclerosis, polycystic ovarian syndrome, hypertension, ischemia, stroke, heart disease, irritable bowel disorder, inflammation, and cataracts.
Also included in the invention is the use of one or more glucose reabsorption inhibitors in combination with one or more antidiabetic agents for the preparation of a medicament for treating a condition selected from IDDM, NIDDM, IGT, IFG, obesity, nephropathy, neuropathy, retinopathy, atherosclerosis, polycystic ovarian syndrome, hypertension, ischemia, stroke, heart disease, irritable bowel disorder, inflammation, and cataracts.

DETAILED DESCRIPTION OF THE INVENTION

All diabetics, regardless of their genetic and environmental backgrounds, have in common an apparent lack of insulin or inadequate insulin function. Because transfer of glucose from the blood into muscle and fatty tissue is insulin dependent, diabetics lack the ability to utilize glucose adequately, which leads to undesired accumulation of glucose in the blood (hyperglycemia). Chronic hyperglycemia leads to decrease in insulin secretion and contributes to increased insulin resistance, and as a result, the blood glucose concentration is increased so that diabetes is self-exacerbated (Diabetologia, 1985, “Hyperglycaemia as an inducer as well as a consequence of impaired isle cell function and insulin resistance: implications for the management of diabetes”, Vol. 28, p. 119); Diabetes Cares, 1990, Vol. 13, No. 6, “Glucose Toxicity”, pp. 610-630). Therefore, by treating hyperglycemia, the aforementioned self-exacerbating cycle is interrupted so that the prophylaxis or treatment of diabetes is made possible.
U.S. Pat. No. 6,153,632 to R. Rieveley discloses a method and composition stated to be for the treatment of diabetes mellitus (Type I, Impaired Glucose Tolerance [“IGT”] and Type II), which incorporates a therapeutic amount of one or more insulin sensitizers along with one or more of an orally ingested insulin, an injected insulin, a sulfonylurea, a biguanide or an alpha-glucosidase inhibitor for the treatment of diabetes mellitus.
According to one aspect, the invention features the combination of a PPAR modulator, preferably a PPAR δ agonist, and an SGLT inhibitor, preferably an SGLT 2 inhibitor or a selective SGLT 2 inhibitor.

A. TERMS

Some terms are defined below and by their usage throughout this disclosure.
Unless otherwise noted, “alkyl” and “alkoxy” as used herein, whether used alone or as part of a substituent group, include straight, cyclic, and branched-chain alkyl having 1 to 8 carbon atoms, or any number within this range. For example, alkyl radicals include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, 2-butenyl, 2-butynyl, n-pentyl, 3-(2-methyl)butyl, 2-pentyl, 2-methylbutyl, neopentyl, n-hexyl, 2-hexyl and 2-methylpentyl. Alkoxy radicals are oxygen ethers formed from the previously described straight or branched chain alkyl groups. The alkyl and alkoxy group may be independently substituted with one to five, preferably one to three groups selected from halogen (F, Cl, Br, I), oxo, OH, amino, carboxyl, and alkoxy. The alkyl and alkoxy group may also be independently linked to one or more PEG radicals (polyethylene glycol).
The term “acyl” as used herein, whether used alone or as part of a substituent group, means an organic radical having a carbonyl group linked to hydrocarbyl group having 1 to 7 carbon atoms (branched or straight chain or cyclic) derived from an organic acid by removal of the hydroxyl group. For example C₄acyl can include (CO)CH₂CH₂CH₂CH₃and (CO)(CH₂(CH) (CH₃)₂; similarly, C₆acyl includes both (CO)(C₆H₁₃) and (CO)(C₆H₅). The term “Ac” as used herein, whether used alone or as part of a substituent group, means acetyl.
“Aryl” is a carbocyclic aromatic radical including, but not limited to, phenyl, 1- or 2-naphthyl and the like. The carbocyclic aromatic radical may be substituted by independent replacement of 1 to 3 of the hydrogen atoms thereon with halogen, OH, CN, mercapto, nitro, amino, cyano, optionally substituted C₁-C₈-alkyl, optionally substituted alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkyl-amino, di(C₁-C₈-alkyl)amino, formyl, carboxyl, alkoxycarbonyl, alkoxycarbonyloxy, alkanoyloxy, phenyl, carbamoyl, carboxamide, di-lower alkylcarbamoyloxy, phenoxycarbonyloxy group, lower alkylenedioxy, benzoyloxy, alkyl-CO—O—, alkyl-O—CO—, —CONH₂, alkyl-O—CO—O—, or alkyl-CO—NH—. Illustrative aryl radicals include, for example, phenyl, naphthyl, biphenyl, indene
indane
fluorophenyl, difluorophenyl, benzyl, benzoyloxyphenyl, carboethoxyphenyl, acetylphenyl, ethoxyphenyl, phenoxyphenyl, hydroxyphenyl, carboxyphenyl, trifluoromethylphenyl, methoxyethylphenyl, acetamidophenyl, tolyl, xylyl, dimethylcarbamylphenyl and the like. “Ph” or “PH” denotes phenyl.
The term “heteroaryl” as used herein represents a stable five or six-membered monocyclic or bicyclic aromatic ring system which consists of carbon atoms and from one to three heteroatoms selected from N, O and S. The heteroaryl group may be attached at any heteroatom or carbon atom, which results in the creation of a stable structure. Examples of heteroaryl groups include, but are not limited to benzofuranyl, benzothiophenyl, pyridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, thiophenyl, furanyl, imidazolyl, isoxazolyl, oxazolyl, pyrazolyl, pyrrolyl, thiazolyl, thiadiazolyl, triazolyl, benzimidazolyl, benzofuranyl, benzothienyl, benzisoxazolyl, benzoxazolyl, benzopyrazolyl, indolyl, benzothiazolyl, benzothiadiazolyl, benzotriazolyl or quinolinyl. Preferred heteroaryl groups include pyridinyl, thiophenyl, furanyl, and quinolinyl. When the heteroaryl group is substituted, the heteroaryl group may have one to three substituents which are independently selected from halogen, OH, CN, mercapto, nitro, amino, cyano, optionally substituted C₁-C₈-alkyl, optionally substituted alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkyl-amino, di(C₁-C₈-alkyl)amino, formyl, carboxyl, alkoxycarbonyl, alkoxycarbonyloxy, alkanoyloxy, phenyl, carbamoyl, carboxamide, di-lower alkylcarbamoyloxy, phenoxycarbonyloxy group, lower alkylenedioxy, benzoyloxy, alkyl-CO—O—, alkyl-O—CO—, —CONH₂, alkyl-O—CO—O—, or alkyl-CO—NH—.
The terms “heterocycle,” “heterocyclic,” and “heterocyclyl” refer to an optionally substituted, fully or partially saturated, aromatic or nonaromatic, cyclic group which is, for example, a 4- to 7-membered monocyclic, 7- to 11-membered (or 9-10 membered) bicyclic (heterobicyclyl), or 10- to 15-membered tricyclic ring system, which has at least one heteroatom in at least one carbon atom containing ring. Each ring of the heterocyclic group containing a heteroatom may have 1, 2, or 3 heteroatoms selected from nitrogen atoms, oxygen atoms, and sulfur atoms, where the nitrogen and sulfur heteroatoms may also optionally be oxidized. The nitrogen atoms may optionally be quaternized. The heterocyclic group may be attached at any heteroatom or carbon atom.
Exemplary monocyclic heterocyclic groups include pyrrolidinyl; oxetanyl; pyrazolinyl; imidazolinyl; imidazolidinyl; oxazolyl; oxazolidinyl; isoxazolinyl; thiazolidinyl; isothiazolidinyl; tetrahydrofuryl; piperidinyl; piperazinyl; 2-oxopiperazinyl; 2-oxopiperidinyl; 2-oxopyrrolidinyl; 4-piperidonyl; tetrahydropyranyl; tetrahydrothiopyranyl; tetrahydrothiopyranyl sulfone; morpholinyl; thiomorpholinyl; thiomorpholinyl sulfoxide; thiomorpholinyl sulfone; 1,3-dioxolane; dioxanyl; thietanyl; thiiranyl; and the like. Exemplary bicyclic heterocyclic groups (or heterobicyclyls) include quinuclidinyl; tetrahydroisoquinolinyl; dihydroisoindolyl; dihydroquinazolinyl (such as 3,4-dihydro-4-oxo-quinazolinyl); dihydrobenzofuryl; dihydrobenzothienyl; dihydrobenzothiopyranyl; dihydrobenzothiopyranyl sulfone; dihydrobenzopyranyl; indolinyl; isochromanyl; benzimidazolyl; benzthiazolyl; isoindolinyl; piperonyl; tetrahydroquinolinyl; and the like. When the heteroaryl group is substituted, the heterocyclyl may be independently substituted with one to five, preferably one to three groups selected from halogen, OH, CN, mercapto, nitro, amino, cyano, optionally substituted C₁-C₈-alkyl, optionally substituted alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkyl-amino, di(C₁-C₈-alkyl)amino, formyl, carboxyl, alkoxycarbonyl, alkoxycarbonyloxy, alkanoyloxy, phenyl, carbamoyl, carboxamide, di-lower alkylcarbamoyloxy, phenoxycarbonyloxy group, lower alkylenedioxy, benzoyloxy, alkyl-CO—O—, alkyl-O—CO—, —CONH₂, alkyl-O—CO—O—, or alkyl-CO—NH—.
The term “biaryl” includes a heteroaryl linked to a phenyl, a phenyl linked to a heteroaryl (such as furan, pyridine, or thiophene), and a phenyl linked to a phenyl. Examples of phenyl-phenyl, heteroaryl-phenyl, heteroaryl-phenyl, and, phenyl-heteroaryl, respectively, include:
The term “composition” is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combinations of the specified ingredients in the specified amounts.
The term “combined administration” includes co-administration wherein: 1) the two or more agents are administered to a subject at substantially similar times; and 2) the two or more agents are administered to a subject at different times, at independent intervals which may or may not overlap or coincide.
The term “subject” as used herein, refers to an animal, preferably a mammal, most preferably a human, who is the object of treatment, observation or experiment.
The term “RXR modulator” as used herein, refers to Retinoid-X receptor agonists, partial agonists, or antagonists. Preferably the modulator increases insulin sensitivity. According to one aspect, the modulator is an RXR agonist.
Diabetes, Syndrome X, and associated symptoms or complications include such conditions as IDDM, NIDDM, IGT, IFG, obesity, nephropathy, neuropathy, retinopathy, atherosclerosis, polycystic ovarian syndrome, hypertension, ischemia, stroke, heart disease, irritable bowel disorder, inflammation, and cataracts. Examples of a prediabetic state includes IGT and IFG.
Methods are known in the art for determining effective doses for therapeutic and prophylactic purposes for the disclosed pharmaceutical compositions or the disclosed drug combinations, whether or not formulated in the same composition. For therapeutic purposes, the term “jointly effective amount” as used herein, means that amount of each active compound or pharmaceutical agent, alone or in combination, that elicits the biological or medicinal response in a tissue system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes alleviation of the symptoms of the disease or disorder being treated. For prophylactic purposes (i.e., inhibiting the onset or progression of a disorder), the term “jointly effective amount” refers to that amount of each active compound or pharmaceutical agent, alone or in combination, that inhibits in a subject the onset or progression of a disorder as being sought by a researcher, veterinarian, medical doctor or other clinician, the delaying of which disorder is mediated by the modulation of glucose reabsorption activity or other antidiabetic activity (such as RXR activity) or both. Thus, the present invention provides combinations of two or more drugs wherein, for example, (a) each drug is administered in an independently therapeutically or prophylactically effective amount; (b) at least one drug in the combination is administered in an amount that is sub-therapeutic or sub-prophylactic if administered alone, but is therapeutic or prophylactic when administered in combination with the second or additional drugs according to the invention; or (c) both drugs are administered in an amount that is sub-therapeutic or sub-prophylactic if administered alone, but are therapeutic or prophylactic when administered together.
The term “protecting groups” refer to those moieties known in the art that are used to mask functional groups; protecting groups may be removed during subsequent synthetic transformations or by metabolic or other in vivo administration conditions. During any of the processes for preparation of the compounds of the present invention, it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J. F. W. McOmie, Plenum Press, 1973; and T. W. Greene & P. G. M. Wuts, Protective Groups in Organic Synthesis, Third Edition, John Wiley & Sons, 1999. The protecting groups may be removed at a convenient subsequent stage using methods known in the art. Examples of hydroxyl and diol protecting groups are provided below.
Protection for the hydroxyl group includes methyl ethers, substituted methyl ethers, substituted ethyl ethers, substitute benzyl ethers, and silyl ethers.

Substituted Methyl Ethers

Examples of substituted methyl ethers include methyoxymethyl, methylthiomethyl, t-butylthiomethyl, (phenyldimethylsilyl)methoxymethyl, benzyloxymethyl, p-methoxybenzyloxymethyl, (4-methoxyphenoxy)methyl, t-butoxymethyl, 4-pentenyloxymethyl, siloxymethyl, 2-methoxyethoxymethyl, 2,2,2-trichloroethoxymethyl, bis(2-chloroethoxy)methyl, 2-(trimethylsilyl)ethoxymethyl, tetrahydropyranyl, 3-bromotetrahydropyranyl, tetrahydrothiopyranyl, 1-methoxycyclohexyl, 4-methoxytetrahydropyranyl, 4-methoxytetrahydrothiopyranyl, 4-methoxytetrahydrothiopyranyl S,S-dioxido, 1-[(2-chloro-4-methyl)phenyl]-4-methoxypiperidin-4-yl, 1,4-dioxan-2-yl, tetrahydrofuranyl, tetrahydrothiofuranyl and 2,3,3a,4,5,6,7,7a-octahydro-7,8,8-trimethyl-4,7-methanobenzofuran-2-yl.

Substituted Ethyl Ethers

Examples of substituted ethyl ethers include 1-ethoxyethyl, 1-(2-chloroethoxy)ethyl, 1-methyl-1-methoxyethyl, 1-methyl-1-benzyloxyethyl, 1-methyl-1-benzyloxy-2-fluoroethyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 2-(phenylselenyl)ethyl, t-butyl, allyl, p-chlorophenyl, p-methoxyphenyl, 2,4-dinitrophenyl, benzyl, and polyethyleneglycol ethers.

Substituted Benzyl Ethers

Examples of substituted benzyl ethers include p-methoxybenzyl, 3,4-dimethoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, p-halobenzyl, 2,6-dichlorobenzyl, p-cyanobenzyl, p-phenylbenzyl, 2- and 4-picolyl, 3-methyl-2-picolyl N-oxido, diphenylmethyl, p, p′-dinitrobenzhydryl, 5-dibenzosuberyl, triphenylmethyl, α-naphthyldiphenylmethyl, p-methoxyphenyldiphenylmethyl, di(p-methoxyphenyl)phenylmethyl, tri(p-methoxyphenyl)methyl, 4-(4′-bromophenacyloxy)phenyldiphenylmethyl, 4,4′,4″-tris(4,5-dichlorophthalimidophenyl)methyl, 4,4′,4″-tris(levulinoyloxyphenyl)methyl, 4,4′,4″-tris(benzoyloxyphenyl)methyl, 3-(Imidazol-1-ylmethyl)bis(4′,4″-dimethoxyphenyl)methyl, 1,1-bis(4-methoxyphenyl)-1′-pyrenyl methyl, 9-anthryl, 9-(9-phenyl)xanthenyl, 9-(9-phenyl-10-oxo)anthryl, 1,3-benzodithiolan-2-yl, and benzisothiazolyl S,S-dioxido.

Silyl Ethers

Examples of silyl ethers include trimethylsilyl, triethylsilyl, triisopropylsilyl, dimethylisopropylsilyl, diethylisopropylsilyl, dimethylthexylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, tribenzylsilyl, tri-p-xylylsilyl, triphenylsilyl, diphenylmethylsilyl, and t-butylmethoxyphenylsilyl.

Esters

In addition to ethers, a hydroxyl group may be protected as an ester. Examples of esters include formate, benzoylformate, acetate, chloroacetate, dichloroacetate, trichloroacetate, trifluoroacetate, methoxyacetate, triphenylmethoxyacetate, phenoxyacetate, p-chlorophenoxyacetate, p-P-phenylacetate, 3-phenylpropionate, 4-oxopentanoate(levulinate), 4,4-(ethylenedithio)pentanoate, pivaloate, adamantoate, crotonate, 4-methoxycrotonate, benzoate, p-phenylbenzoate, 2,4,6-trimethylbenzoate(mesitoate), and polyethyleneglycol esters.

Carbonates

Examples of carbonates include methyl, 9-fluorenylmethyl, ethyl, 2,2,2-trichloroethyl, 2-(trimethylsilyl)ethyl, 2-(phenylsulfonyl)ethyl, 2-(triphenylphosphonio)ethyl, isobutyl, vinyl, allyl, p-nitrophenyl, benzyl, p-methoxybenzyl, 3,4-dimethoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, S-benzyl thiocarbonate, 4-ethoxy-1-naphthyl, methyl dithiocarbonate, and polyethyleneglycol carbonates.

Assisted Cleavage

Examples of assisted cleavage include 2-iodobenzoate, 4-azidobutyrate, 4-nitro-4-methylpentanoate, o-(dibromomethyl)benzoate, 2-formylbenzenesulfonate, 2-(methylthiomethoxy)ethyl carbonate, 4-(methylthiomethoxy)butyrate, and 2-(methylthiomethoxymethyl)benzoate.

Miscellaneous Esters

Examples of miscellaneous esters include 2,6-dichloro-4-methylphenoxyacetate, 2,6-dichloro-4-(1,1,3,3-tetramethylbutyl)phenoxyacetate, 2,4-bis(1,1-dimethylpropyl)phenoxyacetate, chlorodiphenylacetate, isobutyrate, monosuccinoate, (E)-2-methyl-2-butenoate(tigloate), o-(methoxycarbonyl)benzoate, p-P-benzoate, α-naphthoate, nitrate, alkyl N,N,N′,N′-tetramethylphosphorodiamidate, N-phenylcarbamate, borate, dimethylphosphinothioyl, and 2,4-dinitrophenylsulfenate

Sulfonates

Examples of sulfonates include sulfate, methanesulfonate(mesylate), benzylsulfonate, and tosylate.

Protection for 1,2- and 1,3-Diols

Cyclic Acetals and Ketals

Examples of cyclic acetals and ketals include methylene, ethylidene, 1-t-butylethylidene, 1-phenylethylidene, (4-methoxyphenyl)ethylidene, 2,2,2-trichloroethylidene, acetonide (isopropylidene), cyclopentylidene, cyclohexylidene, cycloheptylidene, benzylidene, p-methoxybenzylidene, 2,4-dimethoxybenzylidene, 3,4-dimethoxybenzylidene, and 2-nitrobenzylidene.

Cyclic Ortho Esters

Examples of cyclic ortho esters include methoxymethylene, ethoxymethylene, dimethoxymethylene, 1-methoxyethylidene, 1-ethoxyethylidine, 1,2-dimethoxyethylidene, α-methoxybenzylidene, 1-(N,N-dimethylamino)ethylidene derivative, α-(N,N-dimethylamino)benzylidene derivative, and 2-oxacyclopentylidene.

Silyl Derivatives

Examples of silyl derivatives include di-t-butylsilylene group, and 1,3-(1,1,3,3-tetraisopropyldisiloxanylidene) derivative.

Glucose Reabsorption Inhibitors

One method of treating hyperglycemia is to excrete excessive glucose directly into urine so that the blood glucose concentration is normalized. For example, sodium-glucose cotransporters (SGLTs), primarily found in chorionic membrane of the intestine and the kidney, are a family of proteins actively involved in the normal process of glucose absorption. Among them, SGLT1 is present in intestinal and renal epithelial cells (Lee et al., 1994), whereas SGLT2 is found in the epithelium of the kidney (You et al., 1995, MacKenzie et al., 1994). Glucose absorption in the intestine is primarily mediated by SGLT1, a high-affinity low-capacity transporter with a Na⁺:glucose transport ratio of 2:1. SGLT2, also known as SAAT1, transports Na⁺ and glucose at a ratio of 1:1 and functions as a low-affinity high-capacity transporter. These SGLTs are characterized in Table 1:

TABLE 1

				K_m*	TmG**	K_m*
		Stoichi-	Preferred	in	in	In
ISOFORM	TISSUE	ometry	Substrate	vitro	vitro	vivo

SGLT1	Sm.	2:1	D-glucose	0.1	nd	Nd
	Intestine		D-galactose
	Kidney	2:1	D-glucose	0.39	7.9	0.3
	(S1, S3)		D-galactose
SGLT2	Kidney	1:1	D-glucose	1.64	83	6
(SAAT1)	(S3)

*(mM) for D-glucose
**Maximal transport rate pmol/min/mm

Renal reabsorption of glucose is mediated by SGLT1 and SGLT2 (Silverman et al., 1992; Deetjen et al., 1995). Plasma glucose is filtered in the glomerulus and is transepithelially reabsorbed in the proximal tubules. SGLT1 and SGLT2 are located in the apical plasma membranes of the epithelium and derive their energy from the inward sodium gradient created by the Na⁺/K⁺ ATPase pumps located on the basolateral membrane. Once reabsorbed, the elevated cytosolic glucose is then transported to the interstitial space by facilitated glucose transports (GLUT1 and GLUT2). Therefore, inhibition of SGLTs reduces plasma glucose through suppression of glucose reabsorption in the kidney. A therapeutically or prophylactically effective amount of an SGLT inhibitor, such as that sufficient to increase urine glucose excretion, or to decrease plasma glucose, in a subject by a desired amount per day, can be readily determined using methods established in the art. Recently, it has been found that phlorizin, a natural glycoside present in barks and stems of Rosaceae (e.g., apple, pear, etc.), inhibits Na⁺-glucose co-transporters located in chorionic membrane of the intestine and the kidney. By inhibiting Na⁺-glucose co-transporter activity, phlorizin inhibits the renal tubular glucose reabsorption and promotes the excretion of glucose so that the glucose level in a plasma is controlled at a normal level for a long time via subcutaneous daily administration (Journal of Clinical Investigation, 1987, Vol. 79, p. 1510).
Other SGLT inhibitors include alkyl- and phenyl-glucosides, 1-5-isoquinolinesulfonyl)-2-methylpiperazine-HCl (indirectly via protein kinase C), p-chloromercuribenzoate (PCMB), N,N′-dicyclohexylcarbodiimide (DCCD), copper and cadmium ions, and trivalent lanthanides.

B. COMPOUNDS

The invention features compounds of Formula (I):
wherein
R₁is H, C_1-4alkyl, or R₄R₅N—(CO)—; each of R₄and R₅is independently C_1-5alkyl;
R₂is H, F, Cl or C_1-4alkyl;
R₃is H or C_1-4alkyl, provided that where R₃is C_1-4alkyl, then R₂is H;
Q is —C═O—, or —(CH₂)_n— where n=0, 1, or 2;
P═H, C_1-7acyl, or (C_1-6alkoxy)carbonyl; and
Z is substituted or unsubstituted, and is selected from C_3-7cycloalkyl, phenyl, 5- or 6-membered heterocyclic having 1 or 2 heteroatoms independently selected from N, O, and S, a 9- or 10-membered fused bicyclyl (such as naphthyl), or fused heterobicyclyl, wherein the fused heterobicyclyl has between 1 and 4 heteroatoms (and preferably between 1 and 2 heteroatoms) independently selected from N, O, and S.
Examples of compounds of Formula (I) include those wherein: (a) R₁is H; (b) R₂is H, methyl, or ethyl; (c) Q is —(CH₂)_n— and n is 1 or 2; (d) Z is unsubstituted or independently substituted with between 1 and 3 substituents independently selected from C_1-4alkoxy, phenoxy, C_1-4alkyl, C_3-6cycloalkyl, halo, hydroxy, cyano, amino, C_1-4alkylthio, C_1-4alkylsulfonyl, C_1-4alkylsulfinyl, C_1-4aminoalkyl, mono and di-(C_1-4alkyl)amino, phenyl, C_1-4alkylaminosulfonyl (SO₂NHR), amino-(C_1-4alkylsulfonyl) (NHSO₂R), C_1-4dialkylaminosulfinyl (SONHRR), C_1-4alkylamido (NHCOR), C_1-4alkylcarbamido (CONHR), 5-6 membered heterocyclyl containing between 1 and 3 heteroatoms independently selected from N, S, and O; and wherein the substituent(s) on Z can be further independently substituted with between 1 and 3 substituents independently selected from C_1-4alkoxy, C_1-4alkyl, halo, hydroxy, cyano, amino, mono or di-(C_1-4alkyl)amino and C_1-4alkylthio; (e) Z is 4-substituted phenyl, 3,4-disubstituted phenyl, benzhydryl, substituted or unsubstituted thiophene, biaryl, benzofuranyl, dihydrobenzofuranyl, 4-substituted pyridyl, benzo[b]thienyl, chromanyl, benzothiophenyl, indanyl, or naphthyl; (f) Z is unsubstituted or substituted with between 1 and 2 substituents independently selected from methoxy, ethoxy, fluoro, chloro, methyl, ethyl, propyl, butyl and isopropyl; (g) Z is biphenyl, 4-(3-pyridyl)phenyl, 4-(2-thienyl)phenyl, 2-(5-phenyl)thiophenyl, 4-(1H-pyrazol-1-yl)phenyl, (4-ethyl)phenyl, (4-propyl)phenyl, (4-methoxy)phenyl, dihydrobenzofuran-5-yl, or dihydrobenzofuran-6-yl; (h) R₁is H; and R₂is H, methyl, ethyl, propyl, or isopropyl; (h) Q is —(CH₂)_n—; n is 1 or 2; and R₂is H, methyl or ethyl; (i); P is H, C_1-3acyl, or (C_1-3alkoxy)carbonyl; (j) R₁is H; R₂is H, methyl, or ethyl; Q is —(CH₂)_n— and n is 1 or 2; and Z is 4-substituted phenyl, 3,4-disubstituted phenyl, benzhydryl, substituted or unsubstituted thiophene, biaryl, benzofuranyl, dihydrobenzofuranyl, 4-substituted pyridyl, benzo[b]thienyl, chromanyl, benzothiophenyl, indanyl, ornaphthyl; (k) R₁is H; R₂is H, methyl, or ethyl; wherein Z is 4-substituted phenyl, 3,4-disubstituted phenyl, benzhydryl, substituted or unsubstituted thiophene, biaryl, benzofuranyl, dihydrobenzofuranyl, 4-substituted pyridyl, benzo[b]thienyl, chromanyl, benzothiophenyl, indanyl, or naphthyl; and Z is unsubstituted or substituted with between 1 and 2 substituents independently selected from methoxy, ethoxy, fluoro, chloro, methyl, ethyl, propyl, butyl and isopropyl; (l) and combinations of the above.
Preferred examples include: 2-{3-[2-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-1H-indol-4-yloxy}-β-D-glucopyranoside; 2-{3-[2-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-1-methyl-1H-indol-4-yloxy}-β-D-glucopyranoside; 2-{3-[2-(4-Methoxy-phenyl)-ethyl]-1H-indol-4-yloxy}-β-D-glucopyranoside; 2-[3-(4-Ethyl-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside; 2-[3-(4-Ethyl-benzyl)-1H-indol-4-yloxy]-6-O-methoxycarbonyl-β-D-glucopyranoside; 2-[3-(4-Ethyl-benzyl)-1H-indol-4-yloxy]-6-O-ethoxycarbonyl-β-D-glucopyranoside; 2-[3-(4-Ethyl-benzyl)-1H-indol-4-yloxy]-6-O-hexanoyl-β-D-glucopyranoside; 2-[3-(4-Methyl-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside; 2-(3-Biphenyl-4-ylmethyl-1H-indol-4-yloxy)-β-D-glucopyranoside; 2-[3-(4-Ethoxy-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside; 2-[3-(4-Methylsulfanyl-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside; 2-[3-(4-Ethyl-benzyl)-6-methyl-1H-indol-4-yloxy]-β-D-glucopyranoside; 2-[3-(4-Thiophen-3-yl-benzyl)-1H-indol-4-yloxy]β-D-glucopyranoside; and 2-[3-(4-Pyridin-3-yl-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside.
Further examples of preferred compounds include: 2-{3-[2-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-1H-indol-4-yloxy}-6-O-acetyl-β-D-glucopyranoside; 2-[3-(2-Benzo[1,3]dioxol-5-yl-ethyl)-1H-indol-4-yloxy]-β-D-glucopyranoside; 2-{3-[2-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-ethyl]-1H-indol-4-yloxy}-β-D-glucopyranoside; 2-[3-(2-Naphthalen-2-yl-ethyl)-1H-indol-4-yloxy]-β-D-glucopyranoside; 2-{3-[2-(4-Ethoxy-phenyl)-ethyl]-1H-indol-4-yloxy}-β-D-glucopyranoside; 2-{3-[2-(4-Methoxy-phenyl)-ethyl]-6-methyl-1H-indol-4-yloxy}-β-D-glucopyranoside; 2-[3-(3-Fluoro-4-methyl-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside; 2-[3-(4-Propyl-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside; 2-[3-(4-Isopropyl-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside; 2-[3-(2-Fluoro-biphenyl-4-ylmethyl)-1H-indol-4-yloxy]-β-D-glucopyranoside; 2-[3-(4-Methoxy-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside; 2-[3-(3-Fluoro-4-methoxy-benzyl)-1H-indol-4-yloxy]-D-glucopyranoside; 2-[3-(4-Phenoxy-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside; 2-[3-(4-Chloro-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside; 2-(3-Naphthalen-2-ylmethyl-1H-indol-4-yloxy)-β-D-glucopyranoside and 2-[3-(4-Ethyl-benzyl)-2-methyl-1H-indol-4-yloxy]-β-D-glucopyranoside.
Additional examples of compounds of the invention include: 2-{3-[2-(4-Ethyl-phenyl)-ethyl]-1H-indol-4-yloxy}-β-D-glucopyranoside; 2-[1-Diethylcarbamoyl-3-(4-methoxy-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside; 2-[3-(4-Methoxy-benzyl)-1-methyl-1H-indol-4-yloxy]-β-D-glucopyranoside; 2-[3-(4-Ethyl-benzyl)-1-isopropyl-1H-indol-4-yloxy]-β-D-glucopyranoside; 2-[3-Methyl-2-thienyl(−1H-indol-4-yloxy)-β-D-glucopyranoside; 2-[3-(2,3-Dihydro-benzofuran-5-ylmethyl)-1H-indol-4-yloxy]-β-D-glucopyranoside and 2-[3-(4-Ethylbenzoyl)-1H-indol-4-yloxy]-β-D-glucopyranoside and 2-[3-(4-Methoxy-phenyl)-1H-indol-4-yloxy]-β-D-glucopyranoside.
Additional examples include: 2-[3-(4-Cyclopropyl-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside, 2-[3-(4-Pyrazol-1-yl-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside, 2-[6-Chloro-3-(4-ethyl-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside, 2-[3-(4-Ethyl-benzyl)-6-fluoro-1H-indol-4-yloxy]-β-D-glucopyranoside, 2-[3-(5-Ethyl-thiophen-2-ylmethyl)-1H-indol-4-yloxy]-β-D-glucopyranoside, 2-[3-(5-Propyl-thiophen-2-ylmethyl)-1H-indol-4-yloxy]-β-D-glucopyranoside and 2-[3-(5-Phenyl-thiophen-2-ylmethyl)-1H-indol-4-yloxy]-β-D-glucopyranoside.
The more preferred compounds include: 2-{3-[2-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-1H-indol-4-yloxy}-β-D-glucopyranoside; 2-{3-[2-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-1-methyl-1H-indol-4-yloxy}-β-D-glucopyranoside; 2-[3-(3-Fluoro-4-methyl-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside; 2-[3-(4-Methylsulfanyl-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside; 2-[3-(4-Ethyl-benzyl)-6-methyl-1H-indol-4-yloxy]-β-D-glucopyranoside; 2-[3-(4-Methyl-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside; 2-[3-(4-Ethyl-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside; 2-[3-(4-Ethyl-benzyl)-1H-indol-4-yloxy]-6-O-methoxycarbonyl-β-D-glucopyranoside; 2-[3-(4-Ethyl-benzyl)-1H-indol-4-yloxy]-6-O-ethoxycarbonyl-β-D-glucopyranoside; 2-[3-(4-Propyl-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside; 2-(3-(4-Thiophen-3-yl-benzyl)-1H-indol-4-yloxy)-β-D-glucopyranoside; 2-[3-(4-Cyclopropyl-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside; 2-[3-(4-Pyrazol-1-yl-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside, 2-[6-Chloro-3-(4-ethyl-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside; 2-[3-(4-Ethyl-benzyl)-6-fluoro-1H-indol-4-yloxy]-β-D-glucopyranoside; 2-[3-(5-Ethyl-thiophen-2-ylmethyl)-1H-indol-4-yloxy]-β-D-glucopyranoside and 2-[3-(5-Phenyl-thiophen-2-ylmethyl)-1H-indol-4-yloxy]-β-D-glucopyranoside.
The most preferred compounds are 2-{3-[2-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-1H-indol-4-yloxy}β-D-glucopyranoside; 2-[3-(4-Ethyl-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside; 2-[3-(4-Ethyl-benzyl)-1H-indol-4-yloxy]-6-O-ethoxycarbonyl-β-D-glucopyranoside and 2-(3-(4-Thiophen-3-yl-benzyl)-1H-indol-4-yloxy)-β-D-glucopyranoside.

C. SYNTHETIC METHODS

The compounds of the invention can be made according to traditional organic synthesis methods as well as according to combinatorial or matrix synthesis methods. The following three schemes and chemical Examples 1-38 provide general guidance.
Compounds of this invention where R₃is H and Z is aromatic ring can be prepared as outlined in Schemes 1 and 3. Compounds of formula 1 where R₂is any group other than hydrogen defined in claim 1 can be prepared from commercially available or readily prepared 4-substituted 2-hydroxybenzaldehyde [Acta Chem. Scand. 1999, 53, 258; WO 2003043621] as described by Fresneda et. al. [Tetrahedron 2001, 57, 2355-2363].
Compounds of formula 2 where P₁is benzyl or methyl and P₂is benzenesulfonyl can be prepared by iodination of commercially available 4-benzyloxyindole or 4-methoxyindole or compounds of formula 1 where R₂is any group other than hydrogen defined in Claim 1 using chloroiodide in the presence of a base, such as pyridine, in dichloromethane followed by protection of the indole nitrogen with benzenesulfonyl group.
Compounds of formula 3 can be obtained by coupling compounds of formula 2 with selected aryl or heteroaryl boronic acids under known Suzuki coupling reaction conditions [Miyaura, N.; Suzuki, A.; Chem. Rev. 1995, 95, 2457-2483]. Compounds of formula 3 wherein Z is biaryl can be prepared by either coupling commercially available biarylboronic acids or through two consecutive coupling reactions. The first coupling reaction adds commercially available 4-chlorophenylboronic acid followed by the addition of a second aryl or heteroaryl boronic acid under Suzuki reaction conditions.
The indole nitrogen of compounds of formula 3 can be deprotected with a base, such as potassium hydroxide, in refluxing ethanol to provide compounds of formula 5. The sodium salt of 5 is treated with an alkyl halide to give the N-alkylated (R₁) product followed by palladium catalyzed hydrogenation at 10-30 psi of hydrogen pressure to provide compounds of formula 6.
A compound of formula 2 can also be treated with ethylmagnesium bromide at 0° C. in dry THF followed by addition of an aryl carboxaldehyde to give an indolecarbinaol. The crude indolecarbinol can be reduced with triethylsilane and stannic chloride in dichloromethane at −78° C. to provide compounds of formula 9, wherein n is 1.
The phenol protecting groups of compounds of formula 3 or 9 can be removed with boron tribromide at −78° C. in a chlorinated solvent when P₁is methyl or under catalytic hydrogenation conditions at H₂pressures ranging from 10-40 psi when P₁is benzyl to obtain compounds of formula 4 or 10.
Compounds of this invention where n is 1 or 2 can be prepared as outlined in Schemes 2 and 3. Compounds of formula 1 wherein R₂is hydrogen and R₃is any group other than hydrogen defined in Claim 1 can be prepared from 3-amino-o-cresol or 2-methyl-3-phenylmethoxy aniline [Pitzele, et. al. EP 155635, 1985] as described by Dillard et, al. [J. Med. Chem. 1996, 39, 5119-5136].
Compounds of formula 7 wherein P₁is benzyl can be prepared by formylation of compounds of the formula 1 with phosphorus oxychloride under known reaction conditions. The indole nitrogen of synthesized compounds of formula 7 or commercially available 4-benzyloxy-1H-indole-3-carboxaldehyde can be protected by treatment with either di-tert-butyl dicarbonate or N,N-diethylcarbamyl chloride to give compounds of formula 8. These protected indoles may be treated with ylides under standard Wittig reaction conditions to provide an E/Z mixture of compounds. Reduction of the alkene provides compounds of formula 9, wherein n is 2.
A compound of formula 8 can also be treated with an aryl magnesium bromide in THF to give an indolecarbinol. The crude indolecarbinol can be reduced with triethylsilane and stannic chloride in dichloromethane at −78° C. to provide compounds of formula 9, wherein n is 1.
Alternatively compounds of formula 1 where R₂and P₁are methyl and R₃is hydrogen or commercially available 4-methoxyindole can be treated with substituted benzoyl chlorides using standard Friedel-Craft acylation conditions followed by protection of the indole nitrogen with benzenesulfonyl chloride to provide compounds of formula 11. Further reduction with sodium borohydride in the presence of trifluoroacetic acid in a chlorinated solvent can provide compounds of formula 9. Compounds of formula 11 wherein Z is 4-bromophenyl can be further coupled with substituted aryl or heteroaryl boronic acids under standard Suzuki reaction conditions to provide the biaryl analogs.
The phenol protecting groups of compounds of formula 9 or 11 can be removed with boron tribromide at −78° C. in a chlorinated solvent when P₁is methyl or under catalytic hydrogenation conditions at H₂pressures ranging from 10-40 psi when P₁is benzyl to obtain compounds of formula 10 or 14.
The indole nitrogen of compounds of formula 9 can be deprotected by treatment with trifluoroacetic acid in a chlorinated solvent at 0° C. to remove the BOC group or by treatment with an aqueous base such as sodium hydroxide to remove the N,N-diethylcarbamyl group to yield compounds of formula 12. Further alkylation of the indole nitrogen followed by deprotection of the phenol group as previously described provides compounds of formula 13.
Alternatively, a compound of formula 12 wherein n is 1 and R₃is any group other than hydrogen can be obtained directly from a compound of formula 1 and an aromatic aldehyde in the presence of triethylsilane and trifluoroacetic acid in dichloromethane at 0° C. [Appleton, J. E., et. al., Tetrahedron Letter, 1993, 34,1529].
Compounds of formula 17, wherein Q and Z are defined in claim I and R₁is hydrogen, can be obtained from compounds of formula 15 (which is formula 4 wherein Q is absent, or formula 10 wherein Q is (CH₂)_nand n is 1 or 2, or formula 14, wherein Q is C═O), prepared in Schemes 1 or 2, by glycosidation of the phenol group with 2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl bromide in an appropriate solvent, such as acetone, acetonitrile or DMF, under basic conditions, such as potassium carbonate or lithium carbonate. Deprotection of the indole nitrogen and acetyl groups can be done in one step with a base such as potassium hydroxide or sodium hydroxide in refluxing ethanol to provide compounds of formula 18, wherein P is H.
Compounds of formula 18, wherein Q and Z are defined in Claim I, P is H and R₁is either H or any group other than hydrogen, can be obtained from compounds of formula 16 (which is formula 6 wherein Q is absent, or formula 13 wherein Q is (CH₂)_nand n is 1 or 2), prepared in Schemes 1 and 2, by glycosidation of the phenol group as described above followed by deprotection in an alcoholic solvent such as methanol using mild basic conditions, such as potassium carbonate or sodium methoxide, at room temperature.
Compounds of formula 18, wherein P is H, can be treated with one equivalent of alkyl chloroformate or alkyl acid chloride in collidine to selectively acylate the 6-OH group of the glucose to provide compounds of formula 18, wherein P is acyl or alkoxycarbonyl groups.

D. ADDITIONAL ANTIDIABETIC AGENTS

Antidiabetic agents that can be used, according to the invention, as a second or a third antidiabetic agent in a pharmaceutical composition, formulation, or combination method of treatment (regimen) include, but are not limited to those in Table 2.

TABLE 2

Combination Therapies with SGLT Inhibitors

Mechanism or Class	Drug/Compound

Biguanide (class)	metformin
	Fortamet (metformin XT)
	metformin GR
	metformin XL
	NN-414
	fenofibrate/metformin combo
Insulin Secretagogue	glimeparide
(mech), Sulfonylureas	glyburide/glibenclamide combo
(class)	glyburide/metformin combo
	glipizide
	glipizide/metformin combo
	gliclazide
	chlorpropamide
	tolbutamide
	tolazamide
Insulin Secretagogue	repaglinide
(mech), Meglitinides	nateglinide
(class)	mitiglinide
Alpha-glucosidase	acarbose
inhibitors (mech)	miglitol
	voglibose
	emiglitate
Insulin and Insulin	insulin lispro
analogues (class)	insulin glargine
	insulin detemir
	insulin glulisine
	insulin aspart
	human insulin (Humulin R)
	human insulin (Novolin R
	human insulin (Novolin BR)
	insulin, zinc suspension (Humulin L)
	insulin NHP (Humulin N)
	insulin, zinc suspension (Novolin L)
	insulin NHP (Novolin N)
	insulin, zinc suspension (Humulin U)
	human insulin, regular and NHP mix
	(Humulin 50/50)
	human insulin, regular and NHP mix
	(Humulin 70/30)
	human insulin, regular and NHP mix
	(Novolin 70/30)
Inhaled insulin (class)	Exubera
	AERx Insulin Diabetes Management
	System
	AIR inhaled insulin
Oral insulin (class)	Oralin
PPARgamma (mech)	rosiglitazone
	rosiglitazone/metformin combo
	pioglitazone
	isaglitazone (netoglitazone, MCC-555)
	rosiglitazone/sulfonylurea
	ragaglitazar
	balaglitazone (NN-2344)
	R-483
	rivoglitazone (CS-011)
	FK-614
	SCD-DKY
	tesaglitazar
	T131
	CLX0921
	LY-293111 (VML-295)
	MBX 102
	AA10090
	CDDO (TP-155C)
	DRF-2189
	PHT-46
	farglitazar
	GW-7845
	L-764406
	NC-2100
	PN 2022 (PN 2034)
PPARalpha/gamma dual	MK767/MK0767 (KRP 297)
agonists (mech)	muraglitazar (BMS-298585)
	tesaglitazar
	LY-818
	oxeglitazar (EML-4156)
	LY-929
	BVT-142
	DRF-2655
	DRF-4832
	DRF-4158
	LY-465608
	KT6-207
	LSN-862
PPARalpha Agonist (mech)	Fenofibrate
	Gemfibrozil
	Clofibrate
	Ciprofibrate
	Benzafibrate
	K-111
	LY518674 (LY674)
	KRP-101
	NS-220
	GW-9578
	GW-7647
	GW-9820
	LF-200337
	ST-1929
	Wy-14643
PPARdelta Agonist (mech)	GW501516
	GW-1514
	L-165041
	GW 8547
PPARalpha/delta Dual	GW-2433
Agonist (mech)
PPARgamma/delta Dual	none in the last PPAR CEA
Agonist (mech)
PPARalpha/gamma/delta	CLX-0940
Modulator (mech)
RXR Agonist (mech)
Insulin Seretagogue	Exanatide injectable
(mech), GLP-1 analogue	Exanatide LAR injectable
(class)	Exanantide oral
	Liraglutide
GLP-1 agonist (mech)	exenatide (AC2993)
	liraglutide (NN2211)
	LY-307161
	CJC-113
	ZP10
	GLP-1
	BIM-51077
DPPIV Inhibitor (mech)	LAF-237
	P32/98
	P93/01
	NVP-728
Lipase Inhibitor (mech)	Orlistat
	ATL962
Glucokinase Activator	Ro 28-1675
(mech)	Ro 27-4375
beta-3 Agonist (mech)	LY-337604
	L-796568
	CP-331684
	CP-331679
	CP-114271
	Rafabegron (TAK-677)
	YM-178
	N5984
	GW427353
IBAT Inhibitor (mech)	AZD-7806
	SC-990
	SC-017
	GW-264
HM74a/HM74 Agonist	Acipimox
(mech)
Glucocorticoid	A348441
Antagonist (mech)	A362947
	CP394531
	CP409069
	CP472555
Glycogen Phosphorylase a	NN4201
Inhibitor (mech)	Ingliforib (CP368296)
FXR Antagonist (mech)	GW-4064
LXR Agonist (mech)	GW-3965
	T-0901317
	T-0314407
FXR Antagonist (mech)
GLP-1 Analogue (class)	Albugon
GSK-3beta Inhibitor (mech)
PTP-1b Inhibitor (mech)	ISIS-113715
	KP102
Amylin Receptor Agonist	Pramlintide (symlin/amylin)
NO Scavenger (mech)	NOX-700
11beta-Hydroxysteroid	BVT-3498
Dehydrogenase Inhibitor
Peptide YY hormone	AC162325
Glucagon Antagonist (mech)	NN-2501
PEPCK Inhibitor (mech)	R1438
Somatotropin Release-	SOM230
inhibiting Factor (mech)
CPT-1 Inhibitor (mech)	ST1326
Carboxypeptidase	MLN-4760
Inhibitor (mech)
Leptin analogue (class)	Metrileptin

E. COMBINATIONS

The invention features a combination therapy comprising administering a glucose reabsorption inhibitor, such as an SGLT inhibitor, and at least one antidiabetic agent for the treatment of diabetes or Syndrome X, or associated symptoms or complications thereof. The demonstrated efficacy of SGLT inhibitors in numerous models of NIDDM validates the utility of this drug alone for the treatment of NIDDM in humans. Since glucose reabsorption inhibitors have a mechanism of action distinct from that of other antidiabetic agents, such as RXR modulators, the disclosed combination may have the advantage of reducing the amount of either drug necessary to achieve combined therapeutic or pharmaceutical efficacy, relative to the use of either drug alone, thereby reducing one or more adverse side-effects, which often include weight gain, edema, cardiac hypertrophy, hepatohypertrophy, hypoglycemia, or hepatotoxicity, or any combination thereof.
The invention provides a method for treating diabetes or Syndrome X, or complications thereof in a subject, said method comprising administering to said subject a jointly effective amount of a glucose reabsorption inhibitor in combination with a jointly effective amount of an antidiabetic agent. In one aspect of the invention, antidiabetic agent is an RXR agonist or antagonist that increases insulin sensitivity in the subject. Methods to determine the insulin sensitizing activity of an agent are well known in the art. For example, an insulin sensitizer can increase glucose tolerance in a subject in an oral glucose tolerance test.
Particularly, the diabetes or Syndrome X, or associated symptoms or complication thereof is selected from IDDM, NIDDM, IGT, and IFG.
In particular, the glucose reabsorption inhibitor is a SGLT1 and/or SGLT2 inhibitor. More particularly, the glucose reabsorption inhibitor is selected from a compound of Formula (III) and a derivative thereof.
For use in medicine, the salt or salts of the compounds of Formula (III) refer to non-toxic “pharmaceutically acceptable salt or salts.” Other salts may, however, be useful in the preparation of compounds according to this invention or of their pharmaceutically acceptable salts. Representative organic or inorganic acids include, but are not limited to, hydrochloric, hydrobromic, hydroiodic, perchloric, sulfuric, nitric, phosphoric, acetic, propionic, glycolic, lactic, succinic, maleic, fumaric, malic, tartaric, citric, benzoic, mandelic, methanesulfonic, hydroxyethanesulfonic, benezenesulfonic, oxalic, pamoic, 2-naphthalenesulfonic, p-toluenesulfonic, cyclohexanesulfamic, salicylic, saccharinic or trifluoroacetic acid. Representative basic/cationic salts include, but are not limited to, benzathine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine, procaine, aluminum, calcium, lithium, magnesium, potassium, sodium, or zinc. The compounds of Formula (III) or a pharmaceutically acceptable salt thereof, may include an intramolecular salt thereof, or a solvate or hydrate thereof.

F. ADMINISTRATION, FORMULATION, AND DOSAGES

The utility of the disclosed compounds, compositions, and combinations to treat disorders in glucose and lipid metabolism can be determined according to the procedures well known in the art (see the references listed below), as well as all the procedures described in U.S. Pat. Nos. 5,424,406, 5,731,292, 5,767,094, 5,830,873, 6,048,842, WO 01/16122 and WO 01/16123 which are incorporated herein by reference. The compound may be administered to a patient by any conventional route of administration, including, but not limited to, intravenous, oral, subcutaneous, intramuscular, intradermal and parenteral administration. Preferably, formulations are for oral administration.
The present invention also provides pharmaceutical compositions comprising one or more glucose reabsorption inhibitors and one or more antidiabetic agents in association with a pharmaceutically acceptable carrier.
The daily dosage of the products may be varied over a wide range from 1 to 1000 mg per adult human per day. For oral administration, the compositions are preferably provided in the form of tablets containing, 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100, 150, 200, 250 or 500 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated. The compounds may be administered on a regimen of 1 to 2 times per day. The dosages, however, may be varied depending upon the requirement of the patients, the severity of the condition being treated and the compound being employed. The use of either daily administration or post-periodic dosing may be employed. Preferably these compositions are in unit dosage forms such as tablets, pills, capsules, powders, granules, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampoules, auto-injector devices or suppositories; for oral parenteral, intranasal, sublingual or rectal administration, or for administration by inhalation or insufflation. Alternatively, the composition may be presented in a form suitable for once-weekly or once-monthly administration; for example, an insoluble salt of the active compound, such as the decanoate salt, may be adapted to provide a depot preparation for intramuscular injection. For preparing solid compositions such as tablets, the principal active ingredient or ingredients are mixed with a pharmaceutical carrier, e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g. water, to form a solid preformulation composition containing a homogeneous mixture of one or more glucose reabsorption inhibitors and one or more antidiabetic agents, or a pharmaceutically acceptable salt thereof. When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient or ingredients are dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective dosage forms such as tablets, pills and capsules. This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient or ingredients of the present invention. The tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of material can be used for such enteric layers or coatings, such materials including a number of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.
The liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include, aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions, include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinyl-pyrrolidone or gelatin. The liquid forms in suitably flavored suspending or dispersing agents may also include the synthetic and natural gums, for example, tragacanth, acacia, methyl-cellulose and the like. For parenteral administration, sterile suspensions and solutions are desired. Isotonic preparations which generally contain suitable preservatives are employed when intravenous administration is desired.
Advantageously, the combinations of one or more glucose reabsorption inhibitors of the present invention may be administered, alone or in combination with one or more antidiabetic agents, in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily. Furthermore, one or more glucose reabsorption inhibitors and/or one or more antidiabetic agents according to the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal skin patches well known to those of ordinary skill in that art. To be administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.
For instance, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like. Moreover, when desired or necessary, suitable binders; lubricants, disintegrating agents and coloring agents can also be incorporated into the mixture. Suitable binders include, without limitation, starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum and the like.
Wherein the present invention is directed to the administration of a combination, the compounds may be co-administered simultaneously, sequentially, or in a single pharmaceutical composition. Where the compounds are administered separately, the number of dosages of each compound given per day, may not necessarily be the same, e.g. where one compound may have a greater duration of activity, and will therefore, be administered less frequently.
Optimal dosages to be administered may be readily determined by those skilled in the art, and will vary with the particular compound used, the strength of the preparation, the mode of administration, and the advancement of the disease condition. In addition, factors associated with the particular patient being treated, including patient age, weight, diet and time of administration, will result in the need to adjust dosages.
The novel compositions of the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles. Liposomes can be formed from a variety of lipids, including but not limited to amphipathic lipids such as phosphatidylcholines, sphingomyelins, phosphatidylethanolamines, phophatidylcholines, cardiolipins, phosphatidylserines, phosphatidylglycerols, phosphatidic acids, phosphatidylinositols, diacyl trimethylammonium propanes, diacyl dimethylammonium propanes, and stearylamine, neutral lipids such as triglycerides, and combinations thereof. They may either contain cholesterol or may be cholesterol-free.
From Formula (I) and other disclosed formulae it is evident that some compounds in the compositions of the invention may have one or more asymmetric carbon atoms in their structure. It is intended that the present invention include within its scope the stereochemically pure isomeric forms of the compounds as well as their racemates. Stereochemically pure isomeric forms may be obtained by the application of art known principles. Diastereoisomers may be separated by physical separation methods such as fractional crystallization and chromatographic techniques, and enantiomers may be separated from each other by the selective crystallization of the diastereomeric salts with optically active acids or bases or by chiral chromatography. Pure stereoisomers may also be prepared synthetically from appropriate stereochemically pure starting materials, or by using stereospecific reactions.
Some compounds in the compositions of the present invention may have various individual isomers, such as trans and cis, and various alpha and beta attachments (below and above the plane of the drawing). In addition, where the processes for the preparation of the compounds according to the invention give rise to mixture of stereoisomers, these isomers may be separated by conventional techniques such as preparative chromatography. The compounds may be prepared as a single stereoisomer or in racemic form as a mixture of some possible stereoisomers. The non-racemic forms may be obtained by either synthesis or resolution. The compounds may, for example, be resolved into their components enantiomers by standard techniques, such as the formation of diastereomeric pairs by salt formation. The compounds may also be resolved by covalent linkage to a chiral auxiliary, followed by chromatographic separation and/or crystallographic separation, and removal of the chiral auxiliary. Alternatively, the compounds may be resolved using chiral chromatography. Unless otherwise noted, the scope of the present invention is intended to cover all such isomers or stereoisomers per se, as well as mixtures of cis and trans isomers, mixtures of diastereomers and racemic mixtures of enantiomers (optical isomers) as well.
The therapeutic effect of the glucose reabsorption inhibitor administered in combination with an antidiabetic agent in treating diabetes, Syndrome X, or associated symptoms or complications can be shown by methods known in the art. The following examples of combination treatment with SGLT inhibitors and antidiabetic agents are intended to illustrate the invention but not to limit it.

G. SYNTHETIC CHEMICAL EXAMPLES

One aspect of the invention features compounds of formula (I) as described above in the Summary section, the description, and the appended claims. These disclosed compounds may be made according to traditional synthetic organic chemistry methods or according to matrix or combinatorial chemistry methods. The Schemes and Examples below provde general guidance.
¹HNMR spectra were measured on a Brucker AC-300 (300 MHz) spectrometer using tetramethylsilane (TMS) as an internal standard.

Example 1

2-{3-[2-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-1H-indol-4-yloxy}β-D-glucopyranoside

A. 4-Benzyloxy-3-formyl-indole-1-carboxylic acid diethylamide. To a suspension of sodium hydride (1.52 g, 38 mmol) in anhydrous THF (48 mL) was added dropwise a solution of 4-benzyloxy-1H-indole-3-carbaldehyde (7.93 g, 32 mmol) in anhydrous THF (80 ml) at 0° C. After stirring at 0° C. for 15 min, N,N-diethylcarbamyl chloride (4.76 mL, 38 mmol) was added dropwise into the reaction mixture. The mixture was warmed to room temperature and stirred overnight. The reaction was then quenched with water and extracted with ethyl acetate. The organics were washed with brine, dried over anhydrous sodium sulfate and concentrated in vacuo. The residue was crystallized from ether/hexane to give the title compound (8.93 g, 80%) as a white solid.
B. 4-Benzyloxy-3-[2-(2,3-dihydrobenzofuran-5-yl)-vinyl]indole-1-carboxylic acid diethylamide: To a solution of [(2,3-dihydro-benzofuran-5-yl)methyl]triphenylphosphonium bromide (10 g, 21.05 mmol) (prepared according to: Harrowven, D. C. et al in Tetrahedron, 2001, 57, 4447-4454) in THF (200 mL) at −78° C. was added LDA (10.6 mL, 21.05 mmol) and the resulting reaction mixture was allowed to stir at −78° C. for 1 h. Thereafter, the aldehyde prepared in the previous step (2.5 g, 7.14 mmol) was added and the resulting reaction mixture was allowed to stir at room temperature for 2 h. The reaction mixture was poured onto 0.2 M HCl and extracted with ethyl acetate. The combined ethyl acetate extracts were washed with brine, dried over anhydrous sodium sulfate and concentrated in vacuo. Chromatography (SiO₂, 0-25% Ethyl Acetate-Hexanes eluant) provided the desired compound in quantitative yield.
C. 3-[2-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-4-hydroxy-indole-1-carboxylic acid diethylamide: To a solution of the vinyl urea prepared in step B (400 mg, 0.86 mmol) in EtOAc (10 mL) and EtOH (10 mL) at room temperature was added 10% Pd/C (80 mg) and the resulting reaction mixture was allowed stir in a Parr Shaker under 10 psi hydrogen pressure for 5 h. The reaction mixture upon removal from the Parr Shaker was filtered through a pad of Celite and the filterate concentrated in vacuo. Chromatography (SiO₂, 0-25% Ethyl Acetate-Hexanes eluant) provided 1.1 g of the desired compound (1.62 g theoretical, 68% yield).
D. 2-{3-[2-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-1H-indol-4-yloxy}-2,3,4,6-tetra-O-acetyl-β-D-glucopyranoside: To a solution of the urea prepared in step C (1 g, 2.65 mmol) in acetone (8 mL) at room temperature was added potassium carbonate (1.82 g, 13.2 mmol) followed by 2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl bromide (1.17 g, 5.27 mmol) and the resulting reaction mixture was allowed to stir at room temperature for 72 h. The reaction mixture was filtered through Celite and the filtrate washed with ethyl acetate. The combined organic layers were concentrated in vacuo.
Chromatography (SiO₂, 0-20% Ethyl Acetate-Hexanes eluant) provided 0.54 g of the desired compound (1.87 g theoretical, 29% yield).
E. 2-{3-[2-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-1H-indol-4-yloxy}β-D-glucopyranoside: To a solution of the acetyl indole prepared in step D (530 mg, 0.75 mmol) in ethanol (50 mL) was added 25% NaOH (16 mL) and the resulting reaction mixture was allowed to stir at reflux for 3 h. The reaction mixture was diluted with water (200 mL) and the pH adjusted to 11 with the addition of 1 N HCl. The reaction mixture was then concentrated in vacuo to remove ethanol. The aqueous layer was extracted with ethyl acetate. The combined ethyl acetate extracts were washed with brine, dried over anhydrous magnesium sulfate and concentrated in vacuo. Chromatography (SiO₂, 0-10% MeOH—CH₂Cl₂eluant) provided 290 mg of the desired compound as a white solid (330 mg theoretical yield, 88% yield). ¹HNMR (300 MHz, CD₃OD) δ 7.1 (s, 1H), 7-6.85 (m, 3H), 6.77 (s, 1H), 6.75-6.65 (m, 1H), 6.58 (d, J=8 Hz, 1H), 5.2 (d, J=8 Hz, 1H), 4.47 (t, J=8 Hz, 2H), 3.95-3.85 (m, 1H), 3.75-3.7 (m, 1H), 3.6-3.55 (m, 1H), 3.5-3.4 (m, 3H), 3.15 (t, J=8 Hz, 2H), 3.1-2.9 (m, 4H), 2.9-2.8 (m, 1H). MS: m/z (MH⁺) 442.

Example 2

2-{3-[2-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-1H-indol-4-yloxy}-6-O-acetyl β-D-glucopyranoside

The title compound was isolated as a by-product in Example 1, Part E. ¹HNMR (300 MHz, CD₃OD) δ 7.1-7.05 (m, 1H), 7.0-6.9 (m, 3H), 6.76 (s, 1H), 6.7-6.65 (m, 1H), 6.58 (d, J=8 Hz, 1H), 5.17 (d, J=7 Hz, 1H), 4.46 (t, J=8 Hz, 2H), 4.45-4.35 (m, 1H), 4.25-4.2 (m, 1H), 3.7-3.6 (m, 2H), 3.55-3.4 (m, 2H), 3.3-3.2 (m, 1H), 3.14 (t, J=8 Hz, 2H), 3.1-2.8 (m, 3H), 1.92 (s, 3H). MS: m/z (MH⁺) 484.

Example 3

2-{3-[2-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-1-methyl-1H-indol-4-yloxy}β-D-glucopyranoside

A. 4-Benzyloxy-1-methyl-1H-indole-3-carbaldehyde: To a solution of commercially available 4-benzyloxy-1H-indole-3-carbaldehyde (1 g, 3.98 mmol) in DMF (15 mL) at 0° C. was added NaH (262 mg, 8.75 mmol, 80% dispersion in oil) followed by methyl iodide (0.25 mL, 3.98 mmol) and the resulting reaction mixture was allowed to stir at room temperature for 6 h. The reaction mixture was poured onto water and extracted with ethyl acetate. The combined ethyl acetate extracts were washed with brine, dried over anhydrous sodium sulfate and concentrated in vacuo to provide the desired compound in quantitative yield.
B. 2-{3-[2-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-1-methyl-1H-indol-4-yloxy}β-D-glucopyranoside: The title compound was prepared from 4-benzyloxy-1-methyl-1H-indole-3-carbaldehyde (preparation described in Part A) and [(2,3-dihydro-benzofuran-5-yl)methyl]triphenylphosphonium bromide by the same procedure as described in step B through E in Example 1. ¹HNMR (300 MHz, CDCl₃) δ 7.1-7.0 (m, 1H), 6.95-6.8 (m, 3H), 6.7-6.6 (m, 1H), 6.55-6.5 (m, 1H), 4.95 (d, J=8 Hz, 2H), 4.3-4.3 (m, 1H), 4.0-3.9 (m, 1H), 3.8-3.65 (m, 2H), 3.6 (s, 3H), 3.6-5 (m, 2H), 3.45-3.4 (m, 1H), 3.15-3.0 (m, 3H), 2.95-2.85 (m, 2H), 2.65-2.55 (m, 1H). MS: m/z (MH⁺) 456.

Example 4

2-[3-(2-Benzo[1,3]dioxol-5-yl-ethyl)-1H-indol-4-yloxy]β-D-glucopyranoside

The title compound was prepared from 4-benzyloxy-3-formyl-indole-1-carboxylic acid diethylamide prepared in step A of Example 1 and 5-piperonylmethyl triphenylphosphonium bromide by the same procedure as described in Example 1. ¹HNMR (300 MHz, CD₃COCD₃) δ 9.88 (br s, 1H), 7.05-6.9 (m, 3H), 6.8 (s, 1H), 6.75-6.65 (m, 3H), 5.9 (s, 2H), 5.2 (d, J=7 Hz, 1H), 4.4 (br s, 2H), 3.95-3.85 (m, 1H), 3.8-3.5 (m, 6H), 3.3-3.2 (m, 1H), 3.15-2.85 (m, 6H). MS: m/z (MH⁺) 444.

Example 5

2-{3-[2-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-ethyl]-1H-indol-4-yloxy}-β-D-glucopyranoside

The title compound was prepared from 4-benzyloxy-3-formyl-indole-1-carboxylic acid diethylamide and 2,3-dihydro-benzo[1,4]dioxo-6-meyltriphenylphosphonium bromide by the same procedure as described in Example 1. ¹HNMR (300 MHz, CD₃COCD₃) δ 9.89 (br s, 1H), 7.05-6.95 (m, 3H), 6.8-6.65 (m, 4H), 5.2 (d, J=7 Hz, 1H), 4.4-4.25 (m, 2H), 4.2 (s, 4H), 3.95-3.85 (m, 1H), 3.75-3.55 (m, 6H), 3.3-3.2 (m, 1H), 3.15-2.8 (m, 5H). MS: m/z (M⁺) 457.

Example 6

2-[3-(2-Naphthalen-2-yl-ethyl)-1H-indol-4-yloxy]-β-D-glucopyranoside

The title compound was prepared from 4-benzyloxy-3-formyl-indole-1-carboxylic acid diethylamide and 2-naphthylmethyltriphenylphosphonium chloride by the same procedure as described in Example 1. ¹HNMR (300 MHz, CD₃COCD₃) δ 9.89 (br s, 1H), 7.9-7.75 (m, 4H), 7.55-7.35 (m, 3H), 7.1-6.9 (m, 3H), 6.74 (d, J=7 Hz, 1H), 5.26 (d, J=7 Hz, 1H), 4.5-4.4 (m, 2H), 3.95-3.85 (m, 1H), 3.8-3.55 (m, 6H), 3.45-3.35 (m, 1H), 3.25-3.1 (m, 5H). MS: m/z (M⁺+Na) 472.

Example 7

2-{3-[2-(4-Methoxy-phenyl)-ethyl]-1H-indol-4-yloxy}-β-D-glucopyranoside

The title compound was prepared from 4-benzyloxy-3-formyl-indole-1-carboxylic acid diethylamide and 4-methoxybenzyl triphenyphosphonium chloride by the same procedure as described in Example 1. ¹HNMR (300 MHz, CD₃COCD₃) δ 9.87 (br s, 1H), 7.20 (d, J=7 Hz, 2H), 7.05-6.9 (m, 3H), 6.8 (d, J=8 Hz, 2H), 6.7 (d, J=7 Hz, 1H), 5.2 (d, J=7 Hz, 1H), 4.5-4.3 (m, 2H), 3.95-3.85 (m, 1H), 3.75 (s, 3H), 3.7-3.5 (m, 6H), 3.3-3.2 (m, 1H), 3.15-2.85 (m, 5H). MS: m/z (M⁺) 429.

Example 8

2-{3-[2-(4-Ethoxy-phenyl)-ethyl]-1H-indol-4-yloxy}-β-D-glucopyranoside

The title compound was prepared from 4-benzyloxy-3-formyl-indole-1-carboxylic acid diethylamide and 4-ethoxybenzyl triphenyphosphonium chloride by the same procedure as described in Example 1. ¹HNMR (300 MHz, CD₃COCD₃) δ 9.8 (br s, 1H), 7.2 (d, J=8 Hz, 2H), 7.05-6.95 (m, 3H), 6.8 (d, J=8 Hz, 2H), 6.7 (d, J=7 Hz, 1H), 5.22 (d, J=7 Hz, 1H), 4.0 (q, J=7 Hz, 2H), 3.95-3.85 (m, 1H), 3.75-3.5 (m, 6H), 3.35-3.25 (m, 1H), 3.15-2.9 (m, 5H), 1.35 (t, J=7 Hz, 3H). MS: m/z (M++Na) 466.

Example 9

2-{3-[2-(4-Ethyl-phenyl)-ethyl]-1H-indol-4-yloxy}-β-D-glucopyranoside

The title compound was prepared from 4-benzyloxy-3-formyl-indole-1-carboxylic acid diethylamide and (4-ethylbenzyl)triphenylphosphonium chloride by the same procedure as described in Example 1. ¹HNMR (300 MHz, CD₃COCD₃) δ 9.8 (br s, 1H), 7.2 (d, J=8 Hz, 2H), 7.1 (d, J=8 Hz, 2H), 7.05-6.8 (m, 3H), 6.7 (d, J=7 Hz, 1H), 5.2 (d, J=7 Hz, 1H), 4.5-4.3 (m, 2H), 3.95-3.85 (m, 1H), 3.8-3.5 (m, 6H), 3.35-3.25 (m, 1H), 3.15-2.9 (m, 5H), 2.6 (q, J=7 Hz, 2H), 1.2 (t, J=7 Hz, 3H). MS: m/z (MH⁺) 428.

Example 10

2-{3-[2-(4-Methoxy-phenyl)-ethyl]-6-methyl-1H-indol-4-yloxy}-β-D-glucopyranoside

A. 2-Benzyloxy-4-methylbenzaldehyde: To a solution of commercially available 2-hydroxy-4-methylbenzaldehyde (20 g, 147.05 mmol) in DMF (200 mL) at 0° C. was added sodium hydride (6.47 g, 161.76 mmol, 60% oil dispersion) followed by the dropwise addition of benzyl bromide (19.3 mL, 161.76 mmol). Upon completion of addition of benzyl bromide, the ice bath is removed and the reaction mixture was stirred at room temperature for 4 h. The reaction mixture was poured onto water and extracted with ethyl acetate. The combined ethyl acetate extracts were dried over anhydrous sodium sulfate and concentrated in vacuo. Chromatography (SiO₂, 2-5% EtOAc-Hexanes eluant) provided 29.58 g of the desired product as a white solid (33.24 g theoretical, 89% yield).
B. 2-Azido-3-(2-benzyloxy-4-methyphenyl)-acrylic acid ethyl ester: To a solution of sodium ethoxide (46 mL, 3.1 M in ethanol) in ethanol (50 mL) at −15° C. was added dropwise a solution of the aldehyde prepared in the previous step (4 g, 17.7 mmol) and ethyl azidoacetate (23 mL, 53.09 mmol, 2.3 M solution in dichloromethane) and the resulting reaction mixture was allowed to stir at 15° C. for 72 h. The reaction mixture was poured onto saturated sodium bicarbonate and the extracted with ethyl acetate. The combined ethyl acetate extracts were dried over anhydrous sodium sulfate and concentrated in vacuo. The crude product (4.15 g) was used as is without further purification in the next step of the synthetic sequence.
C. 4-Benzyloxy-6-methyl-1H-indole-2-carboxylic acid ethyl ester: A solution of the azido compound prepared in the previous step (4.15 g) in toluene (60 mL) was refluxed for 18 h. The reaction mixture was concentrated in vacuo. Chromatography (SiO₂, 5-10% EtOAC-Hexanes eluant) provided 2.52 g of the desired product as a yellow solid (5.47 g, 46% yield over two steps).
D. 4-Benzyloxy-6-methyl-1H-indole-2-carboxylic acid: To a solution of the ester prepared in the previous step (500 mg, 1.62 mmol) in tetrahydrofuran (4 mL) at room temperature was added lithium hydroxide (240 mg, 10 mmol) followed by water (2 mL) and methanol (2 mL) and the resulting reaction mixture was allowed to stir at room temperature for 72 h. The reaction mixture was poured onto 15% citric acid and extracted with ethyl acetate. The combined ethyl acetate extracts were dried over anhydrous sodium sulfate and concentrated in vacuo to provide 437 mg of the desired product as an off white solid (455 mg theoretical, 96% yield).
E. 4-Benzyloxy-6-methyl-1H-indole: To a solution of the acid prepared in the previous step (150 mg, 0.53 mmol) in quinoline (2 mL) at room temperature was added copper powder (10 mg, 0.16 mmol) and the resulting reaction mixture was allowed to stir at 235° C. for 900 seconds in a microwave reactor. The reaction mixture was poured onto 1 N HCl and extracted with ethyl acetate. The combined ethyl acetate extracts were dried over anhydrous sodium sulfate and concentrated In vacuo. Chromatography (SiO₂, 10 to 20% Ethyl Acetate-Hexanes eluant) provided 617 mg of the desired product as a dark oil (759 mg theoretical, 81% yield).
F. 4-Benzyloxy-6-methyl-1H-indole-3-carbaldehyde: To a solution of POCl₃(1 mL) in DMF (4 mL) at 0° C. was added indole prepared in the previous step (617 mg, 02.59 mmol) in THF (6 mL) and the resulting reaction mixture was allowed to stir with warming to room temperature for 3 h. The reaction mixture was poured on to saturated sodium bicarbonate and extracted with ethyl acetate. The combined ethyl acetate extracts were dried over anhydrous sodium sulfate and concentrated in vacuo. Chromatography (SiO₂, 40% Ethyl Acetate-Hexanes eluant) provided 220 mg of the desired compound as a pale yellow solid (686 mg theoretical, 32% yield).
G. 4-Benzyloxy-3-formyl-6-methyl-indole-1-carboxylic acid diethylamide: To a solution of aldehyde prepared in the previous step (240 mg, 0.91 mmol) in tetrahydrofuran (6 mL) at room temperature was added sodium hydride (54 mg, 1.35 mmol, 60% dispersion in oil) and the resulting reaction mixture was allowed to stir at room temperature for 0.5 h. Thereafter N,N-diethylcarbamyl chloride (0.17 mL, 1.35 mmol) was added and the reaction mixture was allowed to stir at room temperature for 18 h. The reaction mixture was poured onto water and extracted with ethyl acetate. The combined ethyl extracts were dried over anhydrous sodium sulfate and concentrated in vacuo. Chromatography (SiO₂, 30% EtOAc-Hexanes eluant) provided 290 mg of the desired product as a pale yellow solid (331 mg theoretical, 88% yield).
H. 2-{3-[2-(4-Methoxy-phenyl)-ethyl]-6-methyl-1H-indol-4-yloxy}-β-D-glucopyranoside: The title compound was prepared from 4-benzyloxy-3-formyl-6-methyl-indole-1-carboxylic acid diethylamide and 4-methoxybenzyl triphenyphosphonium chloride by the same procedure as described in Example 1. ¹HNMR (300 MHz, CD₃COCD₃) δ 9.7 (br s, 1H), 7.19 (d, J=8 Hz, 2H), 6.9-6.75 (m, 4H), 6.56 (s, 1H), 5.21 (d, J=7 Hz, 1H), 4.4-4.25 (m, 2H), 3.95-3.85 (m, 1H), 3.75 (s, 3H), 3.7-3.5 (m, 5H), 3.3-3.2 (m, 1H), 3.15-2.8 (m, 4H), 2.8 (s, 3H). MS: m/z (MH⁺) 444.

Example 11

2-[3-(4-Ethyl-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside

A. 4-Benzyloxy-3-(4-ethyl-benzyl)-indole-1-carboxylic acid diethylamide: To a solution of 4-benzyloxy-3-formyl-indole-1-carboxylic acid diethylamide, prepared in step A of Example 1 (1.0 g, 2.8 mmol) in 6 mL of anhydrous THF was added dropwise a 0.5 M solution of 4-ethylphenylmagnesium bromide in anhydrous THF (6.2 mL, 3.1 mmol) at 0° C. The reaction mixture was continued stirring at 0° C. for 30 min, quenched with saturated ammonium chloride solution and extracted with ethyl acetate. The organic extracts were dried over sodium sulfate and concentrated in vacuo. The crude product was used directly in the next step. To a solution of the crude indolecarbinol in 6 mL dichloromethane was added triethylsilane (0.46 g, 4.0 mmol) at −78° C., followed by addition of a 1.0 M solution of stannic chloride in dichloromethane (3.6 mL, 3.6 mmol). The reaction mixture was continued stirring at −78° C. for 20 min, quenched with water and warmed to room temperature. After extraction with dichloromethane, the organic extracts were dried over sodium sulfate, concentrated in vacuo and chromatographed with silica gel eluting with ethyl acetate/hexane (25:100) to provide the title compound (0.91 g, yield: 74%) as colorless oil.
B. 3-(4-Ethyl-benzyl)-4-hydroxy-indole-1-carboxylic acid diethylamide: A solution of Part A (0.91 g, 2.1 mmol) in ethanol (10 mL) and ethyl acetate (20 mL) was hydrogenated over 10% Pd—C (0.18 g) under H₂(14 psi) for 7 h. The catalyst was removed by filtration and the filtrate was concentrated in vacuo. The crude product was purified by chromatography on silica gel eluting with methanol/chloroform (4:100) to provide the title compound (0.42 g, 57%) as a white solid.
C. [1-Diethylcarbamoyl-3-(4-ethyl-benzyl)-1H-indol-4-yloxy]-2,3,4,6-tetra-O-acetyl-]-β-D-glucopyranoside: To a solution of Part B (0.42 g, 1.2 mmol) in acetone (2.4 mL) was added potassium carbonate (0.79 g, 6 mmol), followed by addition of 2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl bromide (1.08 g, 2.6 mmol). The reaction mixture was stirred at room temperature for 24 h. Then solids were filtered and washed with ethyl acetate. The organic extracts were washed with water and brine, dried over anhydrous sodium sulfate and concentrated in vacuo. The crude product was purified by chromatography on silica gel eluting with ethyl acetate/hexane (50:50) to provide the title compound (0.37 g, 45%).
D. 2-[3-(4-Ethyl-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside: Part C (0.37 g, 0.5 mmol) was dissolved in ethanol (30 mL) and 25% aqueous sodium hydroxide (10 mL) and the resulting solution was brought to reflux for 3 h. After cooling to room temperature, the mixture was diluted with water (20 mL), concentrated in vacuo to remove most of ethanol, and extracted with ethyl acetate. The organic extracts were washed with water and brine, dried over anhydrous sodium sulfate and concentrated in vacuo. The crude product was purified by chromatography on silica gel eluting with methanol/chloroform (10:100) to provide the final product (0.16 g, 76%) as an off-white solid. ¹HNMR (300 MHz, CD₃OD) δ 7.18 (d, J=8.0 Hz, 2H), 7.07 (d, J=7.86 Hz, 2H), 7.01-6.97 (m, 2H), 6.68 (s, 1H), 6.66 (d, J=2.21 Hz, 1H), 5.08 (d, J=7.39 Hz, 1H), 4.34 (d, J=16.2 Hz, 1H), 4.25 (d, J=15.9 Hz, 1H), 3.88 (dd, J=2.03, 11.93 Hz, 1H), 3.68 (dd, J=5.42, 12.2 Hz, 1H), 3.50-3.41 (m, 4H), 2.59 (q, J=7.41 Hz, 2H), 1.21 (t, J=7.54 Hz, 3H). MS: m/z (MH⁺) 414.

Example 12

2-[3-(4-Ethyl-benzyl)-1H-indol-4-yloxy]-6-O-methoxycarbonyl-β-D-glucopyranoside

A 1.0 M solution of methyl chloroformate in dichloromethane (0.24 mL, 0.24 mmol) was added dropwise to a solution of 2-[3-(4-ethyl-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside (Example 11, 0.093 g, 0.22 mmol) in 2,4,6-collidine (1 mL) at −30° C. The mixture was warmed to room temperature over the period of 2 h, and stirred at room temperature overnight. The reaction was quenched with the addition of water and the mixture was diluted with diethyl ether. The pH of the aqueous layer was adjusted to pH 7 by addition of cold 1N HCl, and the mixture was extracted with diethyl ether. The organics were washed with brine, dried over anhydrous sodium sulfate and concentrated in vacuo. The crude product was purified by chromatography on silica gel eluting with methanol/chloroform (8:100) to provide the final product (0.052 g, 50%) as an off-white solid. ¹HNMR (300 MHz, CD₃OD) δ 7.18 (d, J=8.15 Hz, 2H), 7.08 (d, J=8.05 Hz, 2H), 7.02-6.93 (m, 2H), 6.64-6.61 (m, 2H), 5.04 (d, J=7.35 Hz, 1H), 4.44 (dd, J=2.21, 11.7 Hz, 1H), 4.35-4.27 (m, 3H), 3.70 (s, 3H), 3.66-3.61 (m, 1H), 3.49-3.40 (m, 2H), 3.38-3.36 (m, 1H), 2.59 (q, J=7.76 Hz, 2H), 1.21 (t, J=7.66 Hz, 3H). MS: m/z (MH⁺) 472.

Example 13

2-[3-(4-Ethyl-benzyl)-1H-indol-4-yloxy]-6-O-ethoxycarbonyl-β-D-glucopyranoside

The title compound was prepared from 2-[3-(4-ethyl-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside (Example 11) and ethyl chloroformate by the same procedure as described in Example 12. ¹HNMR (300 MHz, CD₃OD) δ 7.18 (d, J=8.0 Hz, 2H), 7.08 (d, J=8.0 Hz, 2H), 7.01-6.93 (m, 2H), 6.64 (s, 1H), 6.62 (s, 1H), 5.04 (d, J=7.32 Hz, 1H), 4.43 (dd, J=2.1, 11.7 Hz, 1H), 4.32-4.27 (m, 3H), 4.14-4.06 (m, 2H), 3.66-3.61 (m, 1H), 3.49-3.42 (m, 2H), 3.40-3.36 (m, 1H), 2.59 (q, J=7.76 Hz, 2H), 1.26-1.18 (m, 6H). MS: m/z (MH⁺) 486.

Example 14

2-[3-(4-Ethyl-benzyl)-1H-indol-4-yloxy]-6-O-hexanoyl-β-D-glucopyranoside

A solution of hexanoyl chloride (0.072 mg, 0.53 mmol) in dichloromethane (0.05 mL) was added dropwise to a solution of 2-[3-(4-ethyl-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside (Example 11, 0.22 g, 0.53 mmol) in 2,4,6-collidine (2 mL) at −30° C. The mixture was stirred below 0° C. for 30 min. The reaction was quenched with the addition of water and the mixture was diluted with diethyl ether. The pH of the aqueous layer was adjusted to pH 7 by addition of cold 1N HCl, and the mixture was extracted with diethyl ether. The organics were washed with brine, dried over anhydrous sodium sulfate and concentrated in vacuo. The crude product was purified by chromatography on silica gel eluting with methanol/chloroform (8:100) to provide the final product (0.207 g, 76%) as an off-white solid. ¹HNMR (300 MHz, CD₃OD) δ 7.17 (d, J=8.06 Hz, 2H), 7.07 (d, J=8.12 Hz, 2H), 7.02-6.93 (m, 2H), 6.64-6.61 (m, 2H), 5.03 (d, J=7.31 Hz, 1H), 4.41-4.38 (m, 1H), 4.29-4.20 (m, 3H), 3.65-3.59 (m, 1H), 3.49-3.43 (m, 2H), 3.38-3.36 (m, 1H), 2.59 (q, J=7.42 Hz, 2H), 2.28 (t, J=7.22 Hz, 2H), 1.57-1.52 (m, 2H), 1.27-1.18 (m, 7H), 0.85 (t, J=6.85 Hz, 3H). MS: m/z (MH⁺) 512.

Example 15

2-[3-(4-Methyl-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside

The title compound was prepared from 4-benzyloxy-3-formyl-indole-1-carboxylic acid diethylamide and 4-methylphenylmagnesium bromide by the same procedure as described in Example 11. ¹HNMR (300 MHz, CD₃OD) δ 7.15 (d, J=7.86 Hz, 2H), 7.04 (d, J=7.9 Hz, 2H), 6.99-6.96 (m, 2H), 6.68-6.65 (m, 2H), 5.07 (d, J=7.22 Hz, 1H), 4.32 (d, J=16.1 Hz, 1H), 4.24 (d, J=16.0 Hz, 1H), 3.87 (dd, J=1.79, 11.89 Hz, 1H), 3.68 (dd, J=5.44, 12.1 Hz, 1H), 3.48-3.35 (m, 4H), 2.28 (s, 3H). MS: m/z (MH⁺) 400.

Example 16

2-[3-(3-Fluoro-4-methyl-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside

The title compound was prepared from 4-benzyloxy-3-formyl-indole-1-carboxylic acid diethylamide and 3-fluoro-4-methylphenylmagnesium bromide by the same procedure as described in Example 11. ¹HNMR (300 MHz, CD₃COCD₃) δ 10.01 (brs, 1H), 7.1-6.9 (m, 5H), 6.85-6.8 (m, 1H), 6.7 (d, J=7 Hz, 1H), 5.2 (d, J=7 Hz, 1H), 4.6-4.55 (m, 1H), 4.3 (dd, J=15 Hz, 51 Hz, 2H), 3.95-3.85 (m, 1H), 3.8-3.7 (m, 1H), 3.6-3.5 (m, 4H). MS: m/z (M⁺+Na) 440.

Example 17

2-[3-(4-propyl-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside

The title compound was prepared from 4-benzyloxy-3-formyl-indole-1-carboxylic acid diethylamide and 4-propylphenylmagnesium bromide by the same procedure as described in Example 11. ¹HNMR (300 MHz, CD₃OD) δ 7.17 (d, J=7.91 Hz, 2H), 7.05 (d, J=7.86 Hz, 2H), 7.00-6.94 (m, 2H), 6.68-6.65 (m, 2H), 5.08 (d, J=6.94 Hz, 1H), 4.34 (d, J=16.1 Hz, 1H), 4.25 (d, J=16.0 Hz, 1H), 3.88 (dd, J=1.83, 12.2 Hz, 1H), 3.68 (dd, J=5.43, 12.1 Hz, 1H), 3.49-3.39 (m, 4H), 2.54 (t, J=7.49 Hz, 2H), 1.66-1.58 (m, 2H), 0.93 (t, J=7.31 Hz, 3H). MS: m/z (MH⁺) 428.

Example 18

2-[3-(4-isopropyl-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside

The title compound was prepared from 4-benzyloxy-3-formyl-indole-1-carboxylic acid diethylamide and 4-isopropylphenylmagnesium bromide by the same procedure as described in Example 11. ¹HNMR (300 MHz, CD₃OD) δ 7.19 (d, J=8.07 Hz, 2H), 7.10 (d, J=8.06 Hz, 2H), 7.01-6.94 (m, 2H), 6.68-6.65 (m, 2H), 5.09 (d, J=7.03 Hz, 1H), 4.34 (d, J=15.9 Hz, 1H), 4.24 (d, J=16.0 Hz, 1H), 3.88 (dd, J=1.74, 11.8 Hz, 1H), 3.67 (dd, J=5.42, 12.2 Hz, 1H), 3.49-3.37 (m, 4H), 2.89-2.80 (m, 1H), 1.22 (d, J=7.0 Hz, 6H). MS: m/z (MH⁺) 428.

Example 19

2-(3-Biphenyl-4-ylmethyl-1H-indol-4-yloxy)-β-D-glucopyranoside

The title compound was prepared from 4-benzyloxy-3-formyl-indole-1-carboxylic acid diethylamide and 4-biphenylmagnesium bromide by the same procedure as described in Example 11. ¹HNMR (300 MHz, CD₃OD) δ 7.58 (d, J=8.08 Hz, 2H), 7.50 (d, J=8.11 Hz, 2H), 7.41-7.35 (m, 4H), 7.28 (t, J=7.47 Hz, 1H), 7.02-6.69 (m, 2H), 6.77 (s, 1H), 6.68 (d, J=5.12 Hz, 1H), 5.10 (d, J=7.49 Hz, 1H), 4.44 (d, J=15.9 Hz, 1H), 4.31 (d, J=15.9 Hz, 1H), 3.88 (dd, J=2.09, 12.1 Hz, 1H), 3.66 (dd, J=5.62, 12.0 Hz, 1H), 3.51-3.36 (m, 4H). MS: m/z (MH⁺) 462.

Example 20

2-[3-(2-Fluoro-biphenyl-4-ylmethyl)-1H-indol-4-yloxy]-β-D-glucopyranoside

The title compound was prepared from 4-benzyloxy-3-formyl-indole-1-carboxylic acid diethylamide and 3-fluoro-4-biphenylmagnesium bromide by the same procedure as described in Example 11. ¹HNMR (300 MHz, CD₃OD) δ 7.53-7.50 (m, 2H), 7.43-7.31 (m, 4H), 7.21 (d, J=1.46 Hz, 1H), 7.18-7.00 (m, 3H), 6.87 (s, 1H), 6.71 (dd, J=2.06, 6.62 Hz, 1H), 5.11 (d, J=7.17 Hz, 1H), 4.49 (d, J=15.8 Hz, 1H), 4.29 (d, J=15.9 Hz, 1H), 3.88 (dd, J=2.23, 12.1 Hz, 1H), 3.66 (dd, J=5.66, 12.0 Hz, 1H), 3.52-3.42 (m, 3H), 3.39-3.35 (m, 1H). MS: m/z (MH⁺) 480.

Example 21

2-[1-Diethylcarbamoyl-3-(4-methoxy-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside

[1-Diethylcarbamoyl-3-(4-methoxy-benzyl)-1H-indol-4-yloxy]-2,3,4,6-tetra-O-acetyl-]-β-D-glucopyranoside (0.13 g, 0.19 mmol, prepared from 4-benzyloxy-N,N-diethylcarbamyl indole 3-carboxaldehyde, prepared in step A of Example 1, and 4-methoxyphenyl-magnesium bromide by the same procedure as described in Example 11, Part A, B and C) was dissolved in methanol (1 mL) and chloroform (0.2 mL), followed by addition of excess of potassium carbonate. The resulting mixture was stirred at room temperature overnight. Then solids were filtered and washed with ethyl acetate. The ethyl acetate solution was washed with water and brine, dried over anhydrous sodium sulfate and concentrated in vacuo. The product was purified by chromatography on silica gel, eluting with methanol/chloroform (10:100), to give the title compound (0.03 g, yield: 31%) as a white solid. ¹HNMR (300 MHz, CD₃OD) δ 7.26-7.20 (m, 4H), 6.92-6.86 (m, 3H), 6.68 (s, 1H), 5.12 (d, J=7.11 Hz, 1H), 4.30-4.28 (m, 2H), 3.90-3.80 (m, 1H), 3.79 (s, 3H), 3.77-3.65 (m, 2H), 3.64-3.51 (m, 2H), 3.50-3.40 (m, 5H), 1.22-1.15 (m, 6H). MS: m/z (MH⁺) 515.

Example 22

2-[3-(4-Methoxy-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside

[1-Diethylcarbamoyl-3-(4-methoxy-benzyl)-1H-indol-4-yloxy]-2,3,4,6-tetra-O-ayacetyl-]-βD-glucopyranoside (0.16 g, 0.23 mmol, prepared from 4-benzyloxy-N,N-diethylcarbamyl indole 3-carboxaldehyde prepared in step A of Example 1, and 4-methoxyphenyl-magnesium bromide by the same procedure as described in Example 11, Part A, B and C) was dissolved in ethanol (15 mL) and 25% aqueous sodium hydroxide (5 mL) and the resulting solution was brought to reflux for 3 h. After cooling to room temperature, the mixture was diluted with water (20 mL), concentrated in vacuo to remove most of ethanol, and extracted with ethyl acetate. The organic extracts were washed with water and brine, dried over anhydrous sodium sulfate and concentrated in vacuo. The crude product was purified by chromatography on silica gel eluting with methanol/chloroform (10:100) to provide the final product (0.062 g, 65%) as an off-white solid. ¹HNMR (300 MHz, CD₃OD) δ 7.18 (d, J=8.59 Hz, 2H), 6.98-6.96 (m, 2H), 6.81-6.78 (m, 2H), 6.68-6.65 (m, 2H), 5.08 (d, J=7.25 Hz, 1H), 4.30 (d, J=16.1 Hz, 1H), 4.21 (d, J=16.1 Hz, 1H), 3.88 (dd, J=1.98, 12.2 Hz, 1H), 3.75 (s, 3H), 3.71-3.57 (m, 2H), 3.49-3.40 (m, 3H). MS: m/z (MH⁺) 416.

Example 23

2-[3-(4-Methoxy-benzyl)-1-methyl-1H-indol-4-yloxy]-β-D-glucopyranoside

A. 4-Benzyloxy-3-(4-methoxy-benzyl)-1H-indole: 4-Benzyloxy-3-(4-methoxy-benzyl)-indole-1-carboxylic acid diethylamide (0.38 g, 0.86 mmol, prepared from 4-benzyloxy-3-formyl-indole-1-carboxylic acid diethylamide, prepared in step A of Example 1, and 4-methoxyphenylmagnesium bromide by the same procedure as described in Example 11, Part A) was dissolved in ethanol (15 mL) and 25% aqueous sodium hydroxide (5 mL) and the resulting solution was brought to reflux for 3 h. After cooling to room temperature, the mixture was diluted with water (20 mL), concentrated in vacuo to remove most of ethanol, and extracted with ethyl acetate. The organic extracts were washed with water and brine, dried over anhydrous sodium sulfate and concentrated in vacuo. The crude product (0.25 g, 86%, a yellow solid) was pure and used directly in the next step.
B. 4-Benzyloxy-3-(4-methoxy-benzyl)-1-methyl-1H-indole: To a suspension of sodium hydride (0.029 g, 38 mmol, 60% in oil suspension) in anhydrous DMF (0.5 mL) was added dropwise a solution of Part A (0.24 g, 0.69 mmol) in anhydrous DMF (2 mL) at 0° C. After stirring at 0° C. for 15 min, iodomethane (0.11 g, 0.76 mmol) was added dropwise into the reaction mixture. The mixture was warmed to room temperature and stirred for 30 min. The reaction was then quenched with water and extracted with ethyl acetate. The organics were washed with brine, dried over anhydrous sodium sulfate and concentrated in vacuo. The crude product (0.24 g, 99%, an orange oil) was pure and used directly in the next step.
C. 3-(4-Methoxy-benzyl)-1-methyl-1H-indol-4-ol: A solution of Part B (0.24 g, 0.69 mmol) in ethanol (5 mL) and ethyl acetate (10 mL) was hydrogenated over 10% Pd—C (0.05 g) under H₂(50 psi) for 3 h. The catalyst was removed by filtration and the filtrate was concentrated in vacuo. The crude product was purified by chromatography on silica gel eluting with methanol/chloroform (4:100) to provide the title compound (0.17 g, 92%) as a yellow solid.
D. 2-[3-(4-methoxy-benzyl)-1-methyl-1H-indol-4-yloxy]-β-D-glucopyranoside: To a solution of Part C (0.17 g, 0.63 mmol) in acetone (1 mL) was added potassium carbonate (0.43 g, 3.2 mmol), followed by addition of 2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl bromide (0.51 g, 1.2 mmol). The reaction mixture was stirred at room temperature for 24 h. Then solids were filtered and washed with ethyl acetate. The ethyl acetate solution was washed with water and brine, dried over anhydrous sodium sulfate and concentrated in vacuo. The residue was dissolved in methanol (2 mL) and chloroform (0.5 mL), followed by addition of excess of potassium carbonate. The resulting mixture was stirred at room temperature for 4 h. Then solids were filtered and washed with ethyl acetate. The ethyl acetate solution was washed with water and brine, dried over anhydrous sodium sulfate and concentrated in vacuo. The product was purified by chromatography on silica gel eluting with methanol/chloroform (10:100) to give the final product (0.035 g, yield: 9%) as a white solid. ¹HNMR (300 MHz, CD₃OD) δ7.18 (d, J=8.68 Hz, 2H), 7.07-7.02 (m, 1H), 6.96 (d, J=7.62 Hz, 1H), 6.82-6.79 (d, J=8.6 Hz, 2H), 6.71 (d, J=7.24 Hz, 1H), 6.59 (s, 1H), 5.08 (d, J=7.04 Hz, 1H), 4.30 (d, J=16.0 Hz, 1H), 4.20 (d, J=16.0 Hz, 1H), 3.88 (dd, J=1.79, 12.0 Hz, 1H), 3.75 (s, 3H), 3.71-3.65 (m, 4H), 3.50-3.40 (m, 4H). MS: m/z (MH⁺) 430.

Example 24

2-[3-(3-Fluoro-4-methoxy-benzyl)-1H-indol-4-yloxy]-D-glucopyranoside

The title compound was prepared from 4-benzyloxy-3-formyl-indole-1-carboxylic acid diethylamide, prepared in step A of Example 1, and 3-fluoro-4-methoxyphenylmagnesium bromide by the same procedure as described in Example 11. ¹HNMR (300 MHz, CD₃OD) δ 7.03-6.91 (m, 5H), 6.75 (s, 1H), 6.70-6.67 (m, 1H), 5.08 (d, J=7.46 Hz, 1H), 4.34 (d, J=15.9 Hz, 1H), 4.17 (d, J=16.1 Hz, 1H), 3.87 (dd, J=2.17, 12.1 Hz, 1H), 3.82 (s, 3H), 3.66 (dd, J=5.61, 12.0 Hz, 1H), 3.48-3.34 (m, 4H). MS: m/z (MH⁺) 434.

Example 25

2-[3-(4-Ethoxy-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside

The title compound was prepared from 4-benzyloxy-3-formyl-indole-1-carboxylic acid diethylamide, prepared in step A of Example 1, and 4-ethoxyphenylmagnesium bromide by the same procedure as described in Example 11. ¹HNMR (300 MHz, CD₃OD) δ 7.17 (d, J=8.68 Hz, 2H), 6.99-6.96 (m, 2H), 6.81-6.78 (m, 2H), 6.68 (s, 2H), 6.66 (d, J=2.33 Hz, 2H), 5.09 (d, J=7.34 Hz, 1H), 4.31 (d, J=16.0 Hz, 1H), 4.22 (d, J=15.9 Hz, 1H), 3.99 (q, J=7.01 Hz, 2H), 3.88 (dd, J=1.86, 11.98 Hz, 1H), 3.68 (dd, J=5.26, 12.0 Hz, 1H), 3.50-3.40 (m, 4H), 1.36 (t, J=7.06 Hz, 3H). MS: m/z (MH⁺) 430.

Example 26

2-[3-(4-Phenoxy-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside

The title compound was prepared from 4-benzyloxy-3-formyl-indole-1-carboxylic acid diethylamide, prepared in step A of Example 1, and 4-phenoxyphenylmagnesium bromide by the same procedure as described in Example 11. ¹HNMR (300 MHz, CD₃OD) δ 7.32-7.25 (m, 4H), 7.06-6.93 (m, 5H), 6.87 (d, J=8.68 Hz, 3H), 6.76 (s, 1H), 6.68 (dd, J=2.13, 6.04 Hz, 1H), 5.09 (d, J=6.97 Hz, 1H), 4.39 (d, J=15.6 Hz, 1H), 4.25 (d, J=16.2 Hz, 1H), 3.89 (d, J=11.8 Hz, 1H), 3.67 (dd, J=5.50, 12.0 Hz, 1H), 3.50-3.37 (m, 4H). MS: m/z (MH⁺) 478.

Example 27

2-[3-(4-Methylsulfanyl-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside

A. 4-Hydroxy-3-(4-methylsulfanyl-benzyl)-indole-1-carboxylic acid diethylamide: To a solution of 4-benzyloxy-3-(4-methylsulfanyl-benzyl)-indole-1-carboxylic acid diethylamide (0.63 g, 1.38 mmol, prepared from 4-benzyloxy-3-formyl-indole-1-carboxylic acid diethylamide and 4-methylsulfanyl-phenylmagnesium bromide by the same procedure as described in Example 11, (Part A) and N,N-dimethylaniline (0.57 mL, 4.3 mmol) in dichloromethane (3.2 mL) was added powdered AICl₃(0.75 g, 5.6 mmol) at room temperature. The reaction mixture was stirred for 2 h, quenched by addition of 1 N HCl (9.5 mL) and the aqueous layer was extracted with ethyl acetate. The organics were washed with brine, dried over anhydrous sodium sulfate and concentrated in vacuo. The crude product was purified by chromatography on silica gel, eluting with ethyl acetate/hexane (25:100) to provide the title compound (0.48 g, 96%) as yellow oil.
B. 2-Hydroxymethyl-6-[3-(4-methylsulfanyl-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside: The title compound was prepared from Part A by the same procedure as described in Example 11, Part C and D. ¹HNMR (300 MHz, CD₃OD) δ 7.22 (d, J=8.30 Hz, 2H), 7.16 (d, J=8.19 Hz, 2H), 6.99-6.97 (m, 2H), 6.72 (s, 1H), 6.69-6.66 (m, 1H), 5.09 (d, J=7.17 Hz, 1H), 4.36 (d, J=15.9 Hz, 1H), 4.23 (d, J=16.2 Hz, 1H), 3.88 (dd, J=2.17, 12.1 Hz, 1H), 3.66 (dd, J=5.61, 12.0 Hz, 1H), 3.49-3.39 (m, 4H), 2.43 (s, 3H). MS: m/z (MH⁺) 432.

Example 28

2-[3-(4-Chloro-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside

The title compound was prepared from 4-benzyloxy-3-formyl-indole-1-carboxylic acid diethylamide, prepared in step A of Example 1, and 4-chlorophenylmagnesium bromide by the same procedure as described in Example 11. ¹HNMR (300 MHz, CD₃COCD₃) δ 10.03 (brs, 1H), 7.35 (d, J=8 Hz, 2H), 7.2 (d, J=8 Hz, 2H), 7.1-6.85 (m, 3H), 6.7 (d, J=7 Hz, 1H), 5.11 (d, J=7 Hz, 1H), 4.45-4.15 (m, 5H), 3.95-3.85 (m, 1H), 3.75-3.65 (m, 1H), 3.6-3.4 (m, 5H), 2.93 (s, 1H). MS: m/z (M⁺+Na) 442.

Example 29

2-(3-Naphthalen-2-ylmethyl-1H-indol-4-yloxy)-β-D-glucopyranoside

The title compound was prepared from 4-benzyloxy-3-formyl-indole-1-carboxylic acid diethylamide, prepared in step A of Example 1, and 2-naphthylmethylphenylmagnesium bromide by the same procedure as described in Example 11. ¹HNMR (300 MHz, CD₃COCD₃) δ 10.01 (br s, 1H), 7.9-7.8 (m, 4H), 7.7.55-7.5 (m, 1H), 7.4-7.3 (m, 2H), 7.05-6.9 (M, 2H), 6.85 (m, 1H), 7.6 (1H), 5.13 (d, J=7 Hz, 1H), 4.48 (dd, J=15 Hz, 40 Hz, 2H), 3.9-3.8 (m, 1H), 3.7-3.45 (m, 6H). MS: m/z (M⁺+Na) 458.

Example 30

2-[3-(2,3-Dihydro-benzofuran-5-ylmethyl)-1H-indol-4-yloxy]-β-D-glucopyranoside

The title compound was prepared from 4-benzyloxy-3-formyl-indole-1-carboxylic acid diethylamide, prepared in step A of Example 1, and 2,3-dihydro-benzofuranylmagnesium bromide by the same procedure as described in Example 11. ¹HNMR (300 MHz, CD₃OD) δ 7.11 (s, 1H), 6.98-6.93 (m, 3H), 6.70-6.58 (m, 3H), 5.08 (d, J=7.31 Hz, 1H), 4.47 (t, J=8.66 Hz, 2H), 4.28 (d, J=16.0 Hz, 1H), 4.19 (d, J=16.1 Hz, 1H), 3.90-3.85 (m, 1H), 3.71-3.65 (m, 1H), 3.49-3.40 (m, 4H), 3.12 (m, 2H). MS: m/z (MH⁺) 428.

Example 31

2-[3-(4-Ethyl-benzyl)-1-isopropyl-1H-indol-4-yloxy]-β-D-glucopyranoside

The title compound was prepared from 4-benzyloxy-3-formyl-indole-1-carboxylic acid diethylamide, prepared in step A of Example 1, and 4-ethylphenylmagnesium bromide by the same procedure as described in Example 23. ¹HNMR (300 MHz, CD₃OD) δ 7.17 (d, J=8.15 Hz, 2H), 7.07 (d, J=8.16 Hz, 2H), 7.04-7.02 (m, 2H), 6.80 (s, 1H), 6.70-6.67 (m, 1H), 5.07 (d, J=7.21 Hz, 1H), 4.60-4.65 (m, 1H), 4.34 (d, J=15.9 Hz, 1H), 4.24 (d, J=15.7 Hz, 1H), 3.88 (dd, J=2.16, 12.1 Hz, 1H), 3.70-3.64 (m, 1H), 3.54-3.45 (m, 3H), 2.63-2.56 (m, 2H), 2.59 (q, J=7.52 Hz, 2H), 1.21 (t, J=7.54 Hz, 3H). MS: m/z (MH⁺) 456.

Example 32

2-[3-(4-Ethyl-benzyl)-6-methyl-1H-indol-4-yloxy]-β-D-glucopyranoside

The title compound was prepared from 4-Benzyloxy-3-formyl-6-methyl-indole-1-carboxylic acid diethylamide (Example 9, Part G) and 4-ethylphenylmagnesium bromide by the procedure described in Example 11. ¹HNMR (300 MHz, CD₃OD) δ 9.8 (br s, 1H), 7.4 (d, J=7 Hz, 2H), 7.1 (d, J=7 Hz, 2H), 6.85 (s, 1H), 6.75 (s, 1H), 6.55 (s, 1H), 5.1-5.05 (m, 1H), 4.25 (dd, J=5 Hz, 10 Hz, 2H), 3.95-3.85 (m, 1H), 3.75-3.65 (m, 1H), 3.55-3.3 (m, 4H), 2.55 (q, J=3 Hz, 2H), 2.33 (s, 3H), 1.20 (t, J=3 Hz, 3H). MS: m/z (M⁺) 427.

Example 33

2-[3-(4-Methoxy-phenyl)-1H-indol-4-yloxy]-β-D-glucopyranoside

A. 4-Benzyloxy-3-iodo-1H-indole: To a solution of 4-benzyloxy-1H-indole (1.0 g, 4.5 mmol) in pyridine (2.5 mL) was added dropwise a 1.0 M solution of iodochlororide in dichloromethane (5 mL, 5 mmol) at 0° C. The mixture was continued to stir at 0° C. for 15 min, then warmed to room temperature and stirred for 1 h. The mixture was poured onto ice-water, neutralized with 1 N HCl solution and extracted with ethyl acetate. The organics were washed with brine, dried over anhydrous sodium sulfate and concentrated in vacuo. The residue was crystallized from ethyl acetate/hexane to give the title compound (1.2 g, 77%) as a light pink solid.
B. 1-Benzenesulfonyl-4-benzyloxy-3-iodo-1H-indole: A mixture of Part A (0.35 g, 1 mmol), tetrabutylammonium bromide (0.032 g, 0.1 mmol) and benzenesulfonyl chloride (0.22 g, 1.3 mmol) in 25% aqueous sodium hydroxide (2 mL) and benzene (1.6 mL) was stirred at room temperature overnight. The reaction mixture was quenched by addition of water and extracted with ethyl acetate. The organic layer was washed with water and brine, dried over anhydrous sodium sulfate and concentrated in vacuo. The crude product (0.49 g, 98%, a white solid) was pure and used directly for the next step.
C. 1-Benzenesulfonyl-4-benzyloxy-3-(4-methoxy-phenyl)-1H-indole: A solution of Part B (0.49 g, 1 mmol) in dimethoxyethane (25 mL) was treated with cesium fluoride (0.46 g, 3 mmol), 4-methoxyphenylboronic acid (0.29 g, 1.5 mmol) and 1,1′-bis-(diphenylphosphino)-ferrocenedichloropalladium (II) (73 mg). The mixture was stirred at 84° C. overnight, cooled to room temperature, quenched with water and extracted with ethyl acetate. The organic extracts were dried over anhydrous sodium sulfate, concentrated in vacuo and chromatographed on silica gel eluting with ethyl acetate/hexane (30:100) to give the title compound (0.26 g, 55%).
D. 1-Benzenesulfonyl-3-(4-methoxy-phenyl)-1H-indol-4-ol: A solution of Part C (0.26 g, 0.55 mmol) in ethanol (5 mL) and ethyl acetate (10 mL) was hydrogenated over 10% Pd—C (0.05 g) under H₂(50 psi) for 6 h. The catalyst was removed by filtration and the filtrate was concentrated in vacuo. The crude product was purified by chromatography on silica gel eluting with methanol/chloroform (4:100) to provide the title compound (0.14 g, 67%) as a yellow solid.
E. 2-[3-(4-Methoxy-phenyl)-1H-indol-4-yloxy]-β-D-glucopyranoside: The title compound was prepared from Part D (0.14 g, 0.36 mmol) by the same procedure as described in Example 11, Part C and Part D. ¹HNMR (300 MHz, CD₃OD) δ 7.63-7.60 (m, 2H), 7.15 (s, 1H), 7.10-7.07 (m, 2H), 6.96-6.93 (m, 2H), 6.83-6.80 (m, 1H), 5.07 (d, J=7.25 Hz, 1H), 3.91-3.86 (m, 1H), 3.84 (s, 3H), 3.73-3.67 (m, 1H), 3.44-3.36 (m, 4H). MS: m/z (MH⁺) 402.

Example 34

2-[3-Methyl-2-thienyl(−1H-indol-4-yloxy]-β-D-glucopyranoside

The title compound was prepared from 4-benzyloxy-3-formyl-indole-1-carboxylic acid diethylamide, prepared in step A of Example 1, and 3-methyl2-thienylmagnesium bromide by the same procedure as described in Example 11. ¹HNMR (300 MHz, CD₃OD) δ7.04 (d, J=5.15 Hz, 1H), 7.02-6.99 (m, 2H), 6.82 (d, J=4.98 Hz, 1H), 6.74-6.69 (m, 1H), 6.63 (s, 1H), 5.10 (d, J=7.33 Hz, 1H), 4.44 (d, J=4.72 Hz, 2H), 3.90 (dd, J=1.75, 10.35 Hz, 1H), 3.71 (dd, J=5.15, 6.77 Hz, 1H), 3.57-3.35 (m, 5H), 2.21 (s, 3H). MS: m/z (MH⁺) 406.

Example 35

2-[3-(4-Pyridin-3-yl-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside

A. (4-Bromo-phenyl)-(4-methoxy-1H-indol-3-yl)-methanone: To a mixture of aluminum chloride (7 g, 52.6 mmol) in dichloromethane (400 mL) was added a solution of 4-methoxyindole (4.0 g, 27.2 mmol) in dichloromethane (40 mL) dropwise through an addition funnel. The mixture was stirred at room temperature for 1 h and a solution of 4-bromobenzoylchloride (6 g, 27.2 mmol) in dichloromethane (40 mL) was slowly added. The resulting mixture was stirred at room temperature overnight. The mixture was quenched with MeOH and evaporated to dryness. The residue was diluted with water and extracted with EtOAc. The organic extracts were washed with brine, dried over MgSO₄, filtered and evaporated to dryness. The crude solid product was precipitated with Et₂O and collected by filtration. The solids were then diluted with MeOH and filtered washing with several portions of MeOH. The methanolic filtrate was evaporated in vacuo and chromatographed (EtOAc:Hexane; 1:2) to afford the title compound (1.0 g, 12%).
B. (1-Benzenesulfonyl-4-methoxy-1H-indol-3-yl)-(4-bromo-phenyl)-methanone: A mixture of the compound prepared in the previous step (1 g, 3.0 mmol), tetrabutylammonium bromide (0.098 g, 0.3 mmol) and 25% aqueous NaOH (16 mL) in benzene (16 mL) was stirred vigorously during the addition of sulfonyl chloride (0.75 g, 4.2 mmol). The resulting mixture was stirred at room temperature overnight, diluted with H₂O (60 ml) and washed with EtOAc. The organic extracts were washed with brine, dried over MgSO₄, filtered and evaporated in vacuo to provide the title compound (1.3 g, 91%).
C. 1-Benzenesulfonyl-3-(4-bromo-benzyl)-4-methoxy-1H-indole: Sodium borohydride (2.3 g, 55.3 mmol) was added portionwise over a 30 min period to trifluoroacetic acid (65 mL) pre-cooled in a flask to 0° C. To this mixture was added a solution of the compound prepared in Part B (1.3 g, 2.8 mmol) in CH₂Cl₂(60 mL) through an addition funnel. The resulting mixture was stirred at room temperature overnight, cooled in an ice bath and H₂O (100 mL) was added. Sodium hydroxide (25% solution, 100 mL) was added to a basic pH. Dichloromethane (150 mL) was added and layers were separated. The aqueous layer was extracted with CH₂Cl₂. The combined organic extracts were washed with brine, dried over MgSO₄and evaporated to dryness. The crude product was purified by chromatography (Hexane:EtOAc; 4:1) to provide the title compound (0.81 g, 60%).
D. 1-Benzenesulfonyl-4-methoxy-3-(4-pyridin-3-yl-benzyl)-1H-indole: A mixture of the compound prepared in Part B (0.45 g, 0.98 mmol), 3-pyridylboronic acid (0.21 g, 1.5 mmol), cesium fluoride (0.45 g, 2.96 mmol) and PdCl₂(dppf)₂(0.072 g, 0.099 mmol) in ethylene glycol dimethyl ether (2.5 mL) was stirred at 72° C. for 24 h. The reaction mixture was cooled to room temperature, diluted with H₂O and EtOAc and filtered through CELITE™. The filtrate was washed with brine, dried over MgSO₄, filtered and concentrated in vacuo. The crude product was purified by chromatography (Hexane; EtOAc; 3:2) to provide the title compound (0.31 g, 69%).
E. 1-Benzenesulfonyl-3-(4-pyridin-3-yl-benzyl)-1H-indol-4-ol: A mixture of the compound (0.31 g, 0.68 mmol), prepared in Part D, in dichloromethane (20 mL) was cooled to −78° C. and boron tribromide (1 M solution in CH₂Cl₂; 3.4 mL, 3.4 mmol) was slowly added. The reaction mixture was stirred at −78° C. for 30 minutes then slowly warmed up to room temperature and stirred at for 24 h. A 1 M HCl solution (5 mL) was added dropwise followed by ice H₂O (50 mL). The methylene chloride was removed under reduced pressure and the aqueous mixture extracted with EtOAc. The combined EtOAc extracts was washed with brine, dried over MgSO₄and concentrated to give the title compound as a yellow solid (0.20 g, 67%).
F. 2-[3-(4-Pyridin-3-yl-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside: To a solution of Part E (0.18 g, 0.41 mmol) in acetone (1 mL) was added potassium carbonate (0.28 g, 2.1 mmol), followed by addition of 2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl bromide (0.34 g, 8.2 mmol). The reaction mixture was stirred at room temperature for 2 h and another 2 equivalents of 2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl bromide was added. The mixture was stirred at room temperature for 24 h. Water and EtOAc were added and the mixture filtered through CELITE™. The filtrate was washed with water then brine, dried over MgSO₄and concentrated in vacuo. The residue was purified by chromatography (CH₂Cl₂:Acetone; 20:1) to give pure product. This product was dissolved in EtOH (5 mL) and 50% aqueous KOH (mL) was added. The mixture was stirred in a 75° C. oil bath for 1 h, H₂O was added and the aqueous mixture was carefully neutralized with 10% HCl to pH 9. The EtOH was removed under reduced pressure and the aqueous mixture extracted with EtOAc. The ethyl acetate solution was washed with brine, dried over MgSO₄and concentrated in vacuo. The residue was purified by chromatography on silica gel eluting with methanol/chloroform (10:100) to give the title compound (9.1 mg, 30% yield). ¹HNMR (300 MHz, CD₃OD) δ 8.00 (broad s, 1H), 8.48 (broad s, 1H), 8.06 (d, J=8.25 Hz, 1H), 7.63-7.41 (m, 5H) 7.00 (m, 2H), 6.80 (s, 1H), 6.69-6.67 (m, 1H), 5.10 (d, J=7.2 Hz, 1H), 4.51-4.46 (d, J=15.9 Hz, 1H), 4.35-4.30 (d, J=15.9 Hz, 1H), 3.89-3.85 (dd, J=12.1 Hz, J=2 Hz, 1H), 3.69-3.63 (dd, J=11.8 Hz, J=5.4 Hz, 1H), 3.54-3.36 (m, 4H). MS: m/z (MH⁺) 463.

Example 36

2-[3-(4-Ethyl-benzyl)-2-methyl-1H-indol-4-yloxy]-β-D-glucopyranoside

A. N-(3-Methoxy-2-methyl-phenyl)-acetamide: 1-Methoxy-2-methyl-3-nitro-benzene (0.5 g, 6 mmol) and acetic anhydride (1.14 g, 12 mmol) were dissolved in 48 mL of acetic acid. The mixture was hydrogenated over 10% Pd—C (0.12 g) under H₂(14 psi) for 24 h. The catalyst was removed by filtration and the filtrate was concentrated in vacuo. The crude product was dissolved in ethyl acetate and washed with saturated Na₂CO₃and brine. After drying with anhydrous sodium sulfate, the solvents were removed and the product (1.0 g, 99%) was crystallized in diethyl ether as a white solid.
B. 4-Methoxy-2-methyl-1H-indole: A mixture of Part A (0.72 g, 4 mmol) and sodium amide (0.39 g, 10 mmol) in N,N-diethylaniline (1 mL) was heated to 210° C. over the period of 30 mins. The mixture was stirred at 210° C. for 20 mins, cooled to 90° C., and decomposed with ethanol (0.5 mL) and water (1.5 mL). After cooling to room temperature, the aqueous phase was extracted with diethyl ether. The organic extracts were dried over anhydrous sodium sulfate, concentrated in vacuo and purified by chromatography on silica gel eluting with ethyl acetate/hexane (10:100) to give the title compound (0.19 g, 30%).
C. 3-(4-Ethyl-benzyl)-4-methoxy-2-methyl-1H-indole: A solution of Part B (0.19 g, 1.17 mmol) and 4-ethylbenzaldehyde (0.20 g, 1.5 mmol) in dichloromethane (6 mL) was added in drops to a solution of TFA (0.2 g, 1.8 mmol) and triethylsilane (0.41 g, 3.51 mmol) in dichloromethane (2 mL). The reaction was monitored by TLC until judged complete (20 mins) then basified to pH 8-9 with NaOH (1M) and partitioned between dichloromethane and brine. The organic extracts were dried over anhydrous sodium sulfate, concentrated in vacuo and purified by chromatography on silica gel eluting with chloroform/hexane (20:100) to give the title compound (0.20 g, 61%).
D. 1-Benzenesulfonyl-3-(4-ethyl-benzyl)-4-methoxy-2-methyl-1H-indole: A mixture of the compound as prepared in Part C (0.25 g, 0.9 mmol), tetrabutylammonium bromide (0.032 g, 0.1 mmol) and benzenesulfonyl chloride (0.22 g, 1.3 mmol) in 25% aqueous sodium hydroxide (2 mL) and benzene (2 mL) was stirred at room temperature overnight. The reaction mixture was quenched by addition of water and extracted with ethyl acetate. The organic layer was washed with water and brine, dried over anhydrous sodium sulfate and concentrated in vacuo. The crude product was purified by chromatography on silica gel eluting with chloroform/hexane (10:100) to give the title compound (0.10 g, 27%) as yellow oil.
E. 1-Benzenesulfonyl-3-(4-ethyl-benzyl)-2-methyl-1H-indol-4-ol: To a solution of Part D (0.10 g, 0.24 mmol) in dichloromethane (5 mL) was added a 1.0 M solution of boron tribromide (1 mL, 1 mmol) at −78° C. The reaction mixture was stirred at −78° C. for 30 minutes then slowly warmed up to room temperature and stirred at for 24 h. A 1 M HCl solution (1 mL) was added dropwise followed by ice H₂O (10 mL). The methylene chloride was removed under reduced pressure and the aqueous mixture extracted with EtOAc. The combined organic extracts was washed with brine, dried over sodium sulfate and concentrated. The crude product was purified by chromatography on silica gel eluting with ethyl acetate/hexane (25:100) to give the title compound (0.06 g, 64%) as a light brown solid.
F. 2-[3-(4-Ethyl-benzyl)-2-methyl-1H-indol-4-yloxy]-β-D-glucopyranoside:
The title compound was prepared from Part E as described in Example 11, Part C and D. ¹HNMR (300 MHz, CD₃OD) δ 7.11 (d, J=8.06 Hz, 2H), 7.02 (d, J=7.92 Hz, 2H), 6.95-6.90 (m, 2H), 6.63 (dd, J=7.36, 1.06 Hz, 1H), 5.04 (d, J=7.50 Hz, 1H), 4.38 (d, J=16.0 Hz, 1H), 4.14 (d, J=17.0 Hz, 1H), 3.86 (dd, J=2.15, 12.0 Hz, 1H), 3.65 (dd, J=5.70, 12.1 Hz, 1H), 3.44-3.36 (m, 4H), 2.56 (q, J=7.38 Hz, 2H), 2.29 (s, 3H), 1.18 (t, J=7.66 Hz, 3H). MS: m/z (MH⁺) 414.
MS: m/z (MH⁺) 428.

Example 37

2-[3-(4-Thiophen-3-yl-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside

The title compound was prepared as described in Example 35 substituting the 3-pyridylboronic acid in Part D with 3-thiophinylboronic acid. ¹HNMR (300 MHz, CD₃OD) δ 7.58-7.55 (m, 3H), 7.48-7.45 (m, 2H), 7.34 (m, 2H), 7.05-7.01 (m, 2H), 6.79 (s, 1H), 6.73-6.70 (m, 1H), 5.12 (d, J=7.06 Hz, 1H), 4.47-4.29 (dd, J=15.98 Hz, 2H), 3.93-3.88 (m, 1H), 3.73-3.35 (m, 5H). MS: m/z (MH⁺) 468.

Example 38

2-[3-(4-Ethylbenzoyl)-1H-indol-4-yloxy]-β-D-glucopyranoside

A. (4-Ethyl-phenyl)-(4-methoxy-1H-indol-3-yl)-methanone: To a mixture of aluminum chloride (0.18 g, 1.36 mmol) in dichloromethane (15 mL) was added a solution of 4-methoxyindole (2.0 g, 13.6 mmol) in dichloromethane (10 mL) dropwise. The mixture was stirred at room temperature for 0.5 hr and a solution of 4-Ethylbenzoylchloride (2.29 g, 13.6 mmol) was slowly added. The resulting mixture was stirred at room temperature overnight. The mixture was quenched with water and extracted with EtOAc (3×50 mL). The organic extracts were washed with brine, dried over MgSO₄, filtered and evaporated to dryness. The crude product was purified by chromatography (silica gel, hexane/EtoAc, 4:1) to provide the title compound (0.24 g, 6%).
B. 3-(4-Ethylbenzoyl)-1H-indol-4-ol: To a solution of Part A (0.29 g, 1.04 mmol) in dichloromethane (10 mL) was added a 1.0 M solution of boron tribromide (3.8 mL, 4.16 mmol) at −78° C. The reaction mixture was stirred at −78° C. for 30 minutes then slowly warmed up to room temperature and stirred at RT for 24 h. A 1 M HCl solution (10 mL) was added dropwise followed by ice H₂O (10 mL). The methylene chloride was removed under reduced pressure and the aqueous mixture extracted with EtOAc (3×50 mL). The combined organic extract was washed with brine, dried over sodium sulfate and concentrated. The crude product was washed with ether and filtered. The ether solution was evaporated to dryness to give the title compound (0.085 g, 30%).
C. 2-[3-(4-Ethylbenzoyl)-1H-indol-4-yloxy]-β-D-glucopyranoside: To a solution of Part B (0.08 g, 0.302 mmol) in MeOH (5 mL) was added lithium hydroxide (0.08 g, 3.32 mmol) and the solution was stirred at RT. After 5 min, the solution was evaporated to dryness. 2,3,4,6-tetra-O-acetyl-a-D-glucopyranosyl bromide (0.62 g, 1.51 mmol) was added after diluting the residue in DMF (5 mL). After stirring the reaction mixture at RT overnight, potassium carbonate (0.41 g, 2.97 mmol) and MeOH (5 mL) was added and stirred at RT overnight. The resulting solution was poured into water (20 mL) and the product was extracted with EtOAc (3×50 mL), ether was added and the organic extract was washed with water (4×50 mL) and brine. The combined extract was dried over MgSO₄, filtered and concentrated in vacuo. The residue was purified by chromatography (silica gel, dichloromethane:methanol, 97:3) to give the title compound (0.008 g, 6%) as a white solid. 1 HNMR (300 MHz, CD₃OD) δ 7.95 (s, 1H), 7.78 (d, J=8.09, 2H), 7.40 (d, J=7.89, 2H), 7.19 (m, 2H), 6.65 (d, J=7.47, 1H), 5.47 (d, J=9.09, 1H), 3.80 (m, 4H), 3.54 (m, 2H), 2.77 (q, J=7.47, 2H), 1.30 (t, J=7.59, 3H). MS: m/z (MH⁺) 428.

F. BIOLOGICAL EXAMPLES

Example 1

Materials and Methods

Cloning of the human SGLT1 and human SGLT2 cDNAs and construction of the mammalian expression vector: The human SGLT1 cDNA (Genbank M24847) was cloned from human small intestine. Human SGLT2 cDNA (Genbank M95549) was cloned from human kidney. Both full cDNAs were subcloned into pcDNA and sequenced to verify the integrity of the construct.
Generation of CHO-K1 cells stably expressing human SGLT1 or human SGLT2: Transfection of CHO-K1 cells was performed using DMRIE-C reagent (Life Technologies, Gaithersburg, Md.). Transfectants were then selected in the presence of the antibiotic G418 (Gibco-BRL, Grand Island, N.Y.) at 400 μg/ml. Individual clones were then characterized using the functional assay described below.
Cell-based assay for sodium-dependent glucose transport: Cell lines stably expressing human SGLT1 or SGLT2 were then used for functional analysis of Na+-dependent glucose uptake. Briefly, cells were plated at a density of 65,000 cells per well in a 96-well plate and allowed to grow for 48 hours. Cells were subsequently washed one time with Assay Buffer (50 mM HEPES pH 7.4, 20 mM Tris, 5 mM KCl, 1 mM MgCl₂, 1 mM CaCl₂and 137 mM NaCl) and treated with compound in the absence or presence of NaCl for 15 minutes. Cells were then labeled with ¹⁴C-α-methylglucopyranoside (AMG, Sigma, St. Louis, Mo.), a non-metabolizable glucose analog specific for sodium-dependent glucose transporters as previously described (Peng, H. and Lever J.E. Post-transcriptional regulation of Na⁺/glucose cotransporter (SGLT1) gene expression in LLC-PK1 cells. J Biol
Chem 1995; 270:20536-20542.). After 2 hours the □abeled cells were washed three times with ice-cold PBS. After aspiration, cells were solubilized using Microscint 20 (Packard, Meriden, Conn.) and Na-dependent ¹⁴C-AMG uptake was quantified by measuring radioactivity. Plates were counted in a TopCount (Packard, Meriden, Conn.). Results are reported as the % inhibition or IC50 value from a representative experiment. Variability for the functional assay was typically within 20%.

Example 2

In Vivo Assay for Efficacy

Male Zucker Diabetic Fatty (ZDF) rats (7-8 weeks) were obtained from Charles River. Animals were maintained on a 12-hour light/dark cycle in a temperature-controlled room. Animals were given ad libitum access to food (standard rodent diet Purina 5008) and water. Animals were fasted for 12 hours prior to initiation of the experiment. On the morning of the experiment, animals were administered vehicle (0.5% methylcellulose) or compound by oral gavage (1 ml/kg). After one hour, animals received an oral glucose challenge (4 ml/kg of 50% solution) and were immediately placed in metabolism cages. Animals were given free access to water and urine was collected for 4 hours. Urinary glucose was quantified using the Trinder Reagent (Sigma).

Example 3

Effects on Plasma Glucose, Plasma Insulin, Plasma Triglycerides, Plasma Free Fatty Acids, Liver Weight, and Body Weight

To examine the effect of an SGLT inhibitor in combination with an RXR agonist, female db/db mice (6-7 weeks of age/Jackson Labs, ME) are treated daily for 11 days with vehicle (0.5% methylcellulose), an RXR agonist (0.1-10 mpk (mg/kg)), an SGLT inhibitor (100 mpk), or an RXR agonist plus SGLT inhibitor. Mice (n=8 animals/group) receive the test compounds or vehicle by oral gavage in a volume of 10 ml/kg of body weight. Body weight is recorded on day 1, prior to dosing, and days 4, 8 and 11. Eighteen hours after the final dose, mice are weighed and anesthetized with CO₂/O₂(70:30). Mice are then bled by retro-orbital sinus puncture into 2 mL heparinized polypropylene tubes on ice. Plasma samples are then assayed for glucose, insulin, triglycerides, and free fatty acids. Livers are excised, weighed and frozen.
The SGLT inhibitors and RXR agonists have distinct mechanisms of action. Improved glycemic control, measured as a decrease in plasma glucose, plasma insulin, plasma free fatty acids, or plasma triglycerides, or a combination thereof, can be observed at lower concentrations of an RXR agonist when given in combination with an SGLT inhibitor. Therefore, a leftward shift in the dose-response curve for effect of an RXR agonist on the above parameters can become apparent. In addition, the weight gain observed following treatment with RXR agonists is less pronounced when given with the SGLT inhibitor, since SGLT inhibitors' promotion of the urinary excretion of glucose and loss of calories from the body is demonstrated by reduction in weight or weight gain. Also, since SGLT inhibitors promote a mild diuresis, the edema (and the edematous weight gain) commonly observed after treatment with RXR agonists can be less pronounced or absent. A reduction in the amount of an RXR agonist necessary to achieve efficacy in turn improves the side-effect profile. The decreased side effects can include such conditions as fatty liver, increased liver weight, body weight gain, heart weight gain, edema, cardiac hypertrophy, hepatohypertrophy, hypoglycemia, and hepatotoxicity, or any combination thereof.

Example 4

Effects on Plasma Glucose, HbA1c, Hematocrit, Plasma Insulin, Plasma Triglycerides, Plasma Free Fatty Acids, Total Cholesterol, HDL, Plasma Drug Levels, Liver Weight, Heart Weight, Fat Content and Body Weight
To examine the effect of an SGLT inhibitor in combination with an RXR agonist, male ZDF rats (6 weeks of age/GMI) are treated daily for 28 days with vehicle (0.5% methylcellulose), an RXR agonist (0.1 mpk-10 mpk), SGLT inhibitor (3-100 mpk), or an RXR agonist plus SGLT inhibitor. Rats (n=8 animals/group) receive the test compounds or vehicle by oral gavage in a volume of 2 ml/kg of body weight. Body weight is recorded on day 1, prior to dosing, and twice a week for the duration of the study. On the day prior to the final dose, animals are fasted overnight. One hour after the final dose, rats are weighed and anesthetized with CO₂/O₂(70:30). Rats are then bled by retro-orbital sinus puncture into 2 mL heparinized polypropylene tubes on ice. Rats then receive a glucose challenge (2 g/kg p.o) and are placed in metabolism cages for the urine collection (4 hours). Animals are then sacrificed and epididymal fat pads, livers, and hearts are excised, weighed and frozen for histological examination. Plasma samples are then assayed for glucose, HbA1c, insulin, hematocrit, plasma drug levels, total cholesterol, HDL, free fatty acids, and triglycerides. Urine volume and urinary glucose, protein, osmolarity, electrolytes (Na, K, Cl), BUN and creatinine are measured.
The SGLT inhibitors and RXR agonists have distinct mechanisms of action. Improved glycemic control, measured as a decrease in plasma glucose, HbA1c, plasma insulin, or plasma triglycerides, or a combination thereof, can be observed at lower concentrations of RXR agonists when given in combination with an SGLT inhibitor. Therefore, a leftward shift in the dose-response curve for effect of RXR agonists on the above parameters can become apparent. In addition, the weight gain observed following treatment with RXR agonists is less pronounced when given with the SGLT inhibitor, since SGLT inhibitors' promotion of the urinary excretion of glucose and loss of calories from the body is demonstrated by reduction in weight or weight gain. Also, since SGLT inhibitors promote a mild diuresis, the edema (and the edematous weight gain) commonly observed after treatment with RXR agonists can be less pronounced or absent. This can be demonstrated by a reduction in the RXR agonist-induced increase in heart weight. A reduction in the amount of RXR agonists necessary to achieve efficacy in turn improves the side-effect profile. The decreased side effects can include such conditions as fatty liver, increased liver weight, body weight gain, heart weight gain, edema, cardiac hypertrophy, hepatohypertrophy, hypoglycemia, and hepatotoxicity, or any combination thereof.
The above examples can also show that the oral administration of an SGLTinhibitor in combination with an antidiabetic agent such as an RXR modulator improve the status of other markers of diabetes mellitus including glycosylated hemoglobin (Hgb A1C) levels. Particularly, the oral administration of an SGLT inhibitor in combination with one or more antidiabetic agents can reduce body weight or body weight gain as well as liver weight or liver weight gain, compared to administration of one or more antidiabetic agents alone.
Thus, for treating diabetes, particularly Type II diabetes mellitus, or Syndrome X, a compound of Formula (I) in combination with one or more antidiabetic agents that increases insulin sensitivity, may be employed comprising administering repeated oral doses of the compound of formula I in the range of about 25 to 1000 mg once or twice daily and repeated doses of the anti-diabetic agent or agents at jointly effective dosages. The jointly effective dosage for antidiabetic agents such as RXR agonists disclosed herein may be readily determined by those skilled in the art based on standard dosage guidelines. In particular, such combined administration can be effective to accomplish reduction of body weight, body weight gain, liver weight, or liver weight gain in the subject.
Additionally, a method comprising (a) administering to a subject a jointly effective amount of a glucose reabsorption inhibitor; and (b) administering to the subject a jointly effective amount of an antidiabetic agent can be used to reduce body weight, body weight gain, or liver weight of the subject in need thereof, wherein the combined administration can be in any order and the combined jointly effective amounts provide the desired therapeutic effect.
Also, a method comprising (a) administering to a subject a jointly effective amount of a glucose reabsorption inhibitor; and (b) administering to the subject a jointly effective amount of an antidiabetic agent can be used to control body weight, body weight gain, liver weight, or liver weight gain of the subject having diabetes, Syndrome X, or associated symptoms or complications, wherein the combined administration can be in any order and the combined jointly effective amounts providing the desired therapeutic effect.
Optimal dosages to be administered may be readily determined by those skilled in the art, and will vary with the particular compound used, the mode of administration, the strength of the preparation and the advancement of the disease condition. In addition, factors associated with the particular patient being treated, including patient's sex, age, weight, diet, time of administration and concomitant diseases, will result in the need to adjust dosages.
While the foregoing specification teaches the principles of the present invention, with examples provided for the purpose of illustration, it will be understood that the practice of the invention encompasses all of the usual variations, adaptations and/or modifications as come within the scope of the following claims and their equivalents.

TABLE 3

Example #	CHOK-SGLT1 IC50 (uM)	CHOK-SGLT2 IC50 (uM)

1	0.148	0.020
3	0.195	0.062
4	0.823	0.098
5	3.38	0.146
6	1.06	0.149
7	0.56	0.142
10	2.73	0.376
8	1.34	0.183
9	46% Inh. @ 10 μM	50% Inh. @ 1 μM
22	1.12	0.118
23	69% Inh. @ 10 μM	1.22
24	79% Inh. @ 10 μM	0.202
27	1.31	0.026
25	49% Inh. @ 10 μM	0.100
15	3.88	0.053
16	42% Inh. @ 3 μM	0.067
11	1.81	0.024
12	0	0.66
13	0	0.65
14	71% Inh. @ 10 μM	0.206
32	30% Inh. @ 10 μM	0.117
31	0	5.11
17	3.2	0.049
18	49% Inh. @ 10 μM	0.088
19	63% Inh. @ 10 μM	0.101
20	35% Inh. @ 10 μM	0.114
35	1.12	0.133
26	0	0.42
28	58% Inh. @ 10 μM	0.346
34	27% Inh. @ 10 μM	5.04
29	68% Inh. @ 10 μM	0.26
30	30% Inh. @ 10 μM	1.87
33	0	37% Inh. @ 10 μM
2	1.36	0.158
21	43% Inh. @ 10 μM	1.43
36	16% Inh. @ 10 μM	52% Inh. @ 10 μM
37	1.89	0.034
38	7% Inh. @ 10 μM	22% Inh. @ 10 μM

Claims

1-21. (canceled)

22. A method for treating diabetes or Syndrome X, or associated symptoms or complications thereof in a mammal, said method comprising administering to a mammal in need of treatment an effective amount of 2-{3-[2-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-1H-indol-4-yloxy}-β-D-glucopyranoside; 2-{3-[2-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-1-methyl-1H-indol-4-yloxy}-β-D-glucopyranoside; 2-{3-[2-(4-Methoxy-phenyl)-ethyl]-1H-indol-4-yloxy}-β-D-glucopyranoside; 2-[3-(4-Ethyl-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside; 2-[3-(4-Ethyl-benzyl)-1H-indol-4-yloxy]-6-O-methoxycarbonyl-β-D-glucopyranoside; 2-[3-(4-Ethyl-benzyl)-1H-indol-4-yloxy]-6-O-ethoxycarbonyl-β-D-glucopyranoside; 2-[3-(4-Ethyl-benzyl)-1H-indol-4-yloxy]-6-O-hexanoyl-β-D-glucopyranoside; 2-[3-(4-Methyl-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside; 2-(3-Biphenyl-4-ylmethyl-1H-indol-4-yloxy)-3-D-glucopyranoside; 2-[3-(4-Ethoxy-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside; 2-[3-(4-Methylsulfanyl-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside; 2-[3-(4-Ethyl-benzyl)-6-methyl-1H-indol-4-yloxy]-β-D-glucopyranoside; 2-[3-(4-Thiophen-3-yl-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside; and 2-[3-(4-Pyridin-3-yl-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside; or a pharmaceutically acceptable salt thereof.

23. The method of claim 22, wherein said diabetes is type II diabetes.

24-52. (canceled)

53. A method for treating diabetes or Syndrome X, or associated symptoms or complications thereof in a mammal, said method comprising administering to a mammal in need of treatment an effective amount of a compound selected from the group consisting of 2-{3-[2-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-1H-indol-4-yloxy}-6-O-acetyl-β-D-glucopyranoside; 2-[3-(2-Benzo[1,3]dioxol-5-yl-ethyl)-1H-indol-4-yloxy]-β-D-glucopyranoside; 2-{3-[2-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-ethyl]-1H-indol-4-yloxy}-β-D-glucopyranoside; 2-[3-(2-Naphthalen-2-yl-ethyl)-1H-indol-4-yloxy]-β-D-glucopyranoside; 2-{3-[2-(4-Ethoxy-phenyl)-ethyl]-1H-indol-4-yloxy}-β-D-glucopyranoside; 2-{3-[2-(4-Methoxy-phenyl)-ethyl]-6-methyl-1H-indol-4-yloxy}-β-D-glucopyranoside; 2-[3-(3-Fluoro-4-methyl-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside; 2-[3-(4-Propyl-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside; 2-[3-(4-Isopropyl-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside; 2-[3-(2-Fluoro-biphenyl-4-ylmethyl)-1H-indol-4-yloxy]-β-D-glucopyranoside; 2-[3-(4-Methoxy-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside; 2-[3-(3-Fluoro-4-methoxy-benzyl)-1H-indol-4-yloxy]-D-glucopyranoside; 2-[3-(4-Phenoxy-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside; 2-[3-(4-Chloro-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside; 2-(3-Naphthalen-2-ylmethyl-1H-indol-4-yloxy)-β-D-glucopyranoside and 2-[3-(4-Ethyl-benzyl)-2-methyl-1H-indol-4-yloxy]-β-D-glucopyranoside; or a pharmaceutically acceptable salt thereof.

54. The method of claim 53, wherein said diabetes is type II diabetes.

55. A method for treating diabetes or Syndrome X, or associated symptoms or complications thereof in a mammal, said method comprising administering to a mammal in need of treatment an effective amount of a compound selected from the group consisting of 2-{3-[2-(4-Ethyl-phenyl)-ethyl]-1H-indol-4-yloxy}-β-D-glucopyranoside; 2-[1-Diethylcarbamoyl-3-(4-methoxy-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside; 2-[3-(4-Methoxy-benzyl)-1-methyl-1H-indol-4-yloxy]-β-D-glucopyranoside; 2-[3-(4-Ethyl-benzyl)-1-isopropyl-1H-indol-4-yloxy]-β-D-glucopyranoside; 2-[3-Methyl-2-thienyl(−1H-indol-4-yloxy]-β-D-glucopyranoside; 2-[3-(2,3-Dihydro-benzofuran-5-ylmethyl)-1H-indol-4-yloxy]-β-D-glucopyranoside and 2-[3-(4-Ethylbenzoyl)-1H-indol-4-yloxy]-β-D-glucopyranoside and 2-[3-(4-Methoxy-phenyl)-1H-indol-4-yloxy]-β-D-glucopyranoside; or a pharmaceutically acceptable salt thereof.

56. The method of claim 55, wherein said diabetes is type II diabetes.

57. A method for treating diabetes or Syndrome X, or associated symptoms or complications thereof in a mammal, said method comprising administering to a mammal in need of treatment an effective amount of a compound selected from the group consisting of 2-[3-(4-Cyclopropyl-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside; 2-[3-(4-Pyrazol-1-yl-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside; 2-[6-Chloro-3-(4-ethyl-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside; 2-[3-(4-Ethyl-benzyl)-6-fluoro-1H-indol-4-yloxy]-β-D-glucopyranoside; 2-[3-(5-Ethyl-thiophen-2-ylmethyl)-1H-indol-4-yloxy]-β-D-glucopyranoside; 2-[3-(5-Propyl-thiophen-2-ylmethyl)-1H-indol-4-yloxy]-β-D-glucopyranoside; and 2-[3-(5-Phenyl-thiophen-2-ylmethyl)-1H-indol-4-yloxy]-β-D-glucopyranoside; or a pharmaceutically acceptable salt thereof.

58. The method of claim 57, wherein said diabetes is type II diabetes.

59. A method for treating diabetes or Syndrome X, or associated symptoms or complications thereof in a mammal, said method comprising administering to a mammal in need of treatment an effective amount of a compound selected from the group consisting 2-{3-[2-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-1H-indol-4-yloxy}-β-D-glucopyranoside; 2-{3-[2-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-1-methyl-1H-indol-4-yloxy}-β-D-glucopyranoside; 2-[3-(3-Fluoro-4-methyl-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside; 2-[3-(4-Methylsulfanyl-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside; 2-[3-(4-Ethyl-benzyl)-6-methyl-1H-indol-4-yloxy]-β-D-glucopyranoside; 2-[3-(4-Methyl-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside; 2-[3-(4-Ethyl-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside; 2-[3-(4-Ethyl-benzyl)-1H-indol-4-yloxy]-6-O-methoxycarbonyl-β-D-glucopyranoside; 2-[3-(4-Ethyl-benzyl)-1H-indol-4-yloxy]-6-O-ethoxycarbonyl-β-D-glucopyranoside; 2-[3-(4-Propyl-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside; 2-(3-(4-Thiophen-3-yl-benzyl)-1H-indol-4-yloxy)-β-D-glucopyranoside; 2-[3-(4-Cyclopropyl-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside; 2-[3-(4-Pyrazol-1-yl-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside, 2-[6-Chloro-3-(4-ethyl-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside; 2-[3-(4-Ethyl-benzyl)-6-fluoro-1H-indol-4-yloxy]-β-D-glucopyranoside; 2-[3-(5-Ethyl-thiophen-2-ylmethyl)-1H-indol-4-yloxy]-β-D-glucopyranoside and 2-[3-(5-Phenyl-thiophen-2-ylmethyl)-1H-indol-4-yloxy]-β-D-glucopyranoside; or a pharmaceutically acceptable salt thereof.

60. The method of claim 59, wherein said diabetes is type II diabetes.

61. A method for treating diabetes or Syndrome X, or associated symptoms or complications thereof in a mammal, said method comprising administering to a mammal in need of treatment an effective amount of a compound selected from the group consisting 2-{3-[2-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-1H-indol-4-yloxy}β-D-glucopyranoside; 2-[3-(4-Ethyl-benzyl)-1H-indol-4-yloxy]-β-D-glucopyranoside; 2-[3-(4-Ethyl-benzyl)-1H-indol-4-yloxy]-6-O-ethoxycarbonyl-β-D-glucopyranoside; and 2-(3-(4-Thiophen-3-yl-benzyl)-1H-indol-4-yloxy)-β-D-glucopyranoside; or a pharmaceutically acceptable salt thereof.

62. The method of claim 61, wherein said diabetes is type II diabetes.